Granulocyte-colony stimulating factor therapy to induce neovascularization in ischemic heart disease

Danish Medical Journal

Volumn 59, Issue 3, 2012, Pages

  Ripa, Rasmus Sejersten ^a  

^a University of Copenhagen   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

CD34 ANTIGEN; CD45 ANTIGEN; FIBROBLAST GROWTH FACTOR 2; GRANULOCYTE COLONY STIMULATING FACTOR; PLACEBO; STROMAL CELL DERIVED FACTOR 1; VASCULOTROPIN A;

ACUTE HEART INFARCTION; ANGIOGENESIS; ARTICLE; CELL HOMING; CONTROLLED CLINICAL TRIAL (TOPIC); DRUG DOSE ESCALATION; DRUG SAFETY; GENE THERAPY; GENE TRANSFER; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE ISCHEMIA; HEART MUSCLE PERFUSION; HUMAN; ISCHEMIC HEART DISEASE; MESENCHYMAL STROMA CELL; META ANALYSIS (TOPIC); MOBILIZATION; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PHASE 1 CLINICAL TRIAL (TOPIC); POSITRON EMISSION TOMOGRAPHY; RANDOMIZED CONTROLLED TRIAL (TOPIC); SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STEM CELL; UNSPECIFIED SIDE EFFECT; DRUG EFFECT; HEART MUSCLE; PATHOLOGY; REGENERATIVE MEDICINE; REVIEW; STEM CELL TRANSPLANTATION;

GENE THERAPY; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; MYOCARDIAL ISCHEMIA; MYOCARDIUM; NEOVASCULARIZATION, PHYSIOLOGIC; REGENERATIVE MEDICINE; STEM CELL TRANSPLANTATION;

EID: 84863604610     PISSN: None     EISSN: 22451919     Source Type: Journal    
DOI: None     Document Type: Article

References (332)

1. McCulloch EA, Till JE. The radiation sensitivity of normal mouse bone marrow cells, determined by quantitative mar-row transplantation into irradiated mice. Radiat Res 1960;13:115-25.
2. Asahara T, Masuda H, Takahashi T, Kalka C, Pastore C, Silver M, Kearne M, Magner M, Isner JM. Bone marrow origin of endothelial progenitor cells responsible for postnatal vascu-logenesis in physiological and pathological neovasculariza-tion. Circ Res 1999;85:221-8.
3. Asahara T, Murohara T, Sullivan A, Silver M, van der ZR, Li T, Witzenbichler B, Schatteman G, Isner JM. Isolation of puta-tive progenitor endothelial cells for angiogenesis. Science 1997;275:964-7.
4. Orlic D, Kajstura J, Chimenti S, Jakoniuk I, Anderson SM, Li B, Pickel J, McKay R, Nadal-Ginard B, Bodine DM, Leri A, Anver-sa P. Bone marrow cells regenerate infarcted myocardium. Nature 2001;410:701-5.
5. Nygren JM, Jovinge S, Breitbach M, Sawen P, Roll W, Hesche-ler J, Taneera J, Fleischmann BK, Jacobsen SE. Bone marrow-derived hematopoietic cells generate cardiomyocytes at a low frequency through cell fusion, but not transdifferentia-tion. Nat Med 2004;10:494-501.
6. Murry CE, Soonpaa MH, Reinecke H, Nakajima H, Nakajima HO, Rubart M, Pasumarthi KB, Virag JI, Bartelmez SH, Poppa V, Bradford G, Dowell JD, Williams DA, Field LJ. Haemato-poietic stem cells do not transdifferentiate into cardiac myo-cytes in myocardial infarcts. Nature 2004;428:664-8.
7. Kastrup J, Jørgensen E, Drvota V. Vascular growth factor and gene therapy to induce new vessels in the ischemic myocar-dium. Therapeutic angiogenesis. Scand Cardiovasc J 2001;35:291-6.
8. Hendel RC, Henry TD, Rocha-Singh K, Isner JM, Kereiakes DJ, Giordano FJ, Simons M, Bonow RO. Effect of intracoronary recombinant human vascular endothelial growth factor on myocardial perfusion: evidence for a dose-dependent effect. Circulation 2000;101:118-21.
9. Henry TD, Annex BH, McKendall GR, Azrin MA, Lopez JJ, Giordano FJ, Shah PK, Willerson JT, Benza RL, Berman DS, Gibson CM, Bajamonde A, Rundle AC, Fine J, McCluskey ER. The VIVA trial: Vascular endothelial growth factor in Ischemia for Vascular Angiogenesis. Circulation 2003;107:1359-65.
10. Henry TD, Rocha-Singh K, Isner JM, Kereiakes DJ, Giordano FJ, Simons M, Losordo DW, Hendel RC, Bonow RO, Eppler SM, Zioncheck TF, Holmgren EB, McCluskey ER. Intracoro-nary administration of recombinant human vascular endo-thelial growth factor to patients with coronary artery dis-ease. Am Heart J 2001;142:872-80.
11. Schumacher B, Pecher P, von Specht BU, Stegmann T. Induc-tion of neoangiogenesis in ischemic myocardium by human growth factors: first clinical results of a new treatment of co-ronary heart disease. Circulation 1998;97:645-50.
12. Laham RJ, Chronos NA, Pike M, Leimbach ME, Udelson JE, Pearlman JD, Pettigrew RI, Whitehouse MJ, Yoshizawa C, Si-mons M. Intracoronary basic fibroblast growth factor (FGF-2) in patients with severe ischemic heart disease: results of a phase I open-label dose escalation study. J Am Coll Cardiol 2000;36:2132-9.
13. Laham RJ, Sellke FW, Edelman ER, Pearlman JD, Ware JA, Brown DL, Gold JP, Simons M. Local perivascular delivery of basic fibroblast growth factor in patients undergoing coro-nary bypass surgery: results of a phase I randomized, double-blind, placebo-controlled trial. Circulation 1999;100:1865-71.
14. Simons M, Annex BH, Laham RJ, Kleiman N, Henry T, Dauer-man H, Udelson JE, Gervino EV, Pike M, Whitehouse MJ, Moon T, Chronos NA. Pharmacological treatment of coro-nary artery disease with recombinant fibroblast growth fac-tor-2: double-blind, randomized, controlled clinical trial. Cir-culation 2002;105:788-93.
15. Sellke FW, Laham RJ, Edelman ER, Pearlman JD, Simons M. Therapeutic angiogenesis with basic fibroblast growth factor: technique and early results. Ann Thorac Surg 1998;65:1540-4.
16. Unger EF, Goncalves L, Epstein SE, Chew EY, Trapnell CB, Cannon RO, III, Quyyumi AA. Effects of a single intracoronary injection of basic fibroblast growth factor in stable angina pectoris. Am J Cardiol 2000;85:1414-9.
17. Ruel M, Laham RJ, Parker JA, Post MJ, Ware JA, Simons M, Sellke FW. Long-term effects of surgical angiogenic therapy with fibroblast growth factor 2 protein. J Thorac Cardiovasc Surg 2002;124:28-34.
18. Udelson JE, Dilsizian V, Laham RJ, Chronos N, Vansant J, Blais M, Galt JR, Pike M, Yoshizawa C, Simons M. Therapeutic an-giogenesis with recombinant fibroblast growth factor-2 im-proves stress and rest myocardial perfusion abnormalities in patients with severe symptomatic chronic coronary artery disease. Circulation 2000;102:1605-10.
19. Yla-Herttuala S, Alitalo K. Gene transfer as a tool to induce therapeutic vascular growth. Nat Med 2003;9:694-701.
20. Symes JF, Losordo DW, Vale PR, Lathi KG, Esakof DD, Mayskiy M, Isner JM. Gene therapy with vascular endothelial growth factor for inoperable coronary artery disease. Ann Thorac Surg 1999;68:830-6.
21. Rosengart TK, Lee LY, Patel SR, Sanborn TA, Parikh M, Berg-man GW, Hachamovitch R, Szulc M, Kligfield PD, Okin PM, Hahn RT, Devereux RB, Post MR, Hackett NR, Foster T, Gras-so TM, Lesser ML, Isom OW, Crystal RG. Angiogenesis gene therapy: phase I assessment of direct intramyocardial admin-istration of an adenovirus vector expressing VEGF121 cDNA to individuals with clinically significant severe coronary ar-tery disease. Circulation 1999;100:468-74.
22. Grines CL, Watkins MW, Helmer G, Penny W, Brinker J, Marmur JD, West A, Rade JJ, Marrott P, Hammond HK, Engler RL. Angiogenic Gene Therapy (AGENT) trial in patients with stable angina pectoris. Circulation 2002;105:1291-7.
23. Losordo DW, Vale PR, Hendel RC, Milliken CE, Fortuin FD, Cummings N, Schatz RA, Asahara T, Isner JM, Kuntz RE. Phase 1/2 placebo-controlled, double-blind, dose-escalating trial of myocardial vascular endothelial growth factor 2 gene trans-fer by catheter delivery in patients with chronic myocardial ischemia. Circulation 2002;105:2012-8.
24. Sylvén C, Sarkar N, Ruck A, Drvota V, Hassan SY, Lind B, Ny-gren A, Kallner Q, Blomberg P, van der LJ, Lindblom D, Brodin LA, Islam KB. Myocardial Doppler tissue velocity improves following myocardial gene therapy with VEGF-A165 plasmid in patients with inoperable angina pectoris. Coron Artery Dis 2001;12:239-43.
25. Vale PR, Losordo DW, Milliken CE, McDonald MC, Gravelin LM, Curry CM, Esakof DD, Maysky M, Symes JF, Isner JM. Randomized, single-blind, placebo-controlled pilot study of catheter-based myocardial gene transfer for therapeutic an-giogenesis using left ventricular electromechanical mapping in patients with chronic myocardial ischemia. Circulation 2001;103:2138-43.
26. Stewart DJ, Hilton JD, Arnold JM, Gregoire J, Rivard A, Archer SL, Charbonneau F, Cohen E, Curtis M, Buller CE, Mendel-sohn FO, Dib N, Page P, Ducas J, Plante S, Sullivan J, Macko J, Rasmussen C, Kessler PD, Rasmussen HS. Angiogenic gene therapy in patients with nonrevascularizable ischemic heart disease: a phase 2 randomized, controlled trial of Ad-VEGF (121) (AdVEGF121) versus maximum medical treat-ment. Gene Ther 2006;13:1503-11.
27. Kastrup J, Jørgensen E, Ruck A, Tägil K, Glogar D, Ruzyllo W, Bøtker HE, Dudek D, Drvota V, Hesse B, Thuesen L, Blomberg P, Gyöngyösi M, Sylvén C. Direct intramyocardial plasmid vascular endothelial growth factor-A165 gene therapy in patients with stable severe angina pectoris A randomized double-blind placebo-controlled study: the Euroinject One trial. J Am Coll Cardiol 2005;45:982-8.
28. Kastrup J, Jørgensen E, Drvota V, Thuesen L, Bøtker HE, Gyöngyösi M, Glogar D, Rück A, Bin Islam K, Sylvén C. Intra-myocardial Injection of Genes with a Novel Percutaneous Technique: Initial Safety Data of the Euroinject One Study. Heart Drug 2001;1:299-304.
29. Gyöngyösi M, Khorsand A, Zamini S, Sperker W, Strehblow C, Kastrup J, Jørgensen E, Hesse B, Tägil K, Bøtker HE, Ruzyllo W, Teresinska A, Dudek D, Hubalewska A, Ruck A, Nielsen SS, Graf S, Mundigler G, Novak J, Sochor H, Maurer G, Glogar D, Sylvén C. NOGA-guided analysis of regional myocardial per-fusion abnormalities treated with intramyocardial injections of plasmid encoding vascular endothelial growth factor A-165 in patients with chronic myocardial ischemia: subanaly-sis of the EUROINJECT-ONE multicenter double-blind rando-mized study. Circulation 2005;112:I157-I165.
30. Kajstura J, Rota M, Whang B, Cascapera S, Hosoda T, Bearzi C, Nurzynska D, Kasahara H, Zias E, Bonafe M, Nadal-Ginard B, Torella D, Nascimbene A, Quaini F, Urbanek K, Leri A, An-versa P. Bone marrow cells differentiate in cardiac cell lineages after infarction independently of cell fusion. Circ Res 2005;96:127-37.
31. Shintani S, Murohara T, Ikeda H, Ueno T, Honma T, Katoh A, Sasaki K, Shimada T, Oike Y, Imaizumi T. Mobilization of en-dothelial progenitor cells in patients with acute myocardial infarction. Circulation 2001;103:2776-9.
32. Wang Y, Johnsen HE, Mortensen S, Bindslev L, Ripa RS, Haack-Sørensen M, Jørgensen E, Fang W, Kastrup J. Changes in circulating mesenchymal stem cells, stem cell homing fac-tor, and vascular growth factors in patients with acute ST elevation myocardial infarction treated with primary percu-taneous coronary intervention. Heart 2006;92:768-74.
33. Wojakowski W, Tendera M, Michalowska A, Majka M, Kucia M, Maslankiewicz K, Wyderka R, Ochala A, Ratajczak MZ. Mobilization of CD34/CXCR4+, CD34/CD117+, c-met+ stem cells, and mononuclear cells expressing early cardiac, muscle, and endothelial markers into peripheral blood in patients with acute myocardial infarction. Circulation 2004;110:3213-20.
34. Leone AM, Rutella S, Bonanno G, Contemi AM, de Ritis DG, Giannico MB, Rebuzzi AG, Leone G, Crea F. Endogenous G-CSF and CD34+ cell mobilization after acute myocardial in-farction. Int J Cardiol 2006;111:202-8.
35. Werner N, Kosiol S, Schiegl T, Ahlers P, Walenta K, Link A, Bohm M, Nickenig G. Circulating endothelial progenitor cells and cardiovascular outcomes. N Engl J Med 2005;353:999-1007.
36. Kocher AA, Schuster MD, Szabolcs MJ, Takuma S, Burkhoff D, Wang J, Homma S, Edwards NM, Itescu S. Neovascularization of ischemic myocardium by human bone-marrow-derived angioblasts prevents cardiomyocyte apoptosis, reduces re-modeling and improves cardiac function. Nat Med 2001;7:430-6.
37. Tse HF, Kwong YL, Chan JK, Lo G, Ho CL, Lau CP. Angiogenesis in ischaemic myocardium by intramyocardial autologous bone marrow mononuclear cell implantation. Lancet 2003;361:47-9.
38. Dohmann HF, Perin EC, Takiya CM, Silva GV, Silva SA, Sousa AL, Mesquita CT, Rossi MI, Pascarelli BM, Assis IM, Dutra HS, Assad JA, Castello-Branco RV, Drummond C, Dohmann HJ, Willerson JT, Borojevic R. Transendocardial autologous bone marrow mononuclear cell injection in ischemic heart failure: postmortem anatomicopathologic and immunohistochemical findings. Circulation 2005;112:521-6.
39. Strauer BE, Brehm M, Zeus T, Bartsch T, Schannwell C, Antke C, Sorg RV, Kogler G, Wernet P, Muller HW, Kostering M. Re-generation of human infarcted heart muscle by intracoro-nary autologous bone marrow cell transplantation in chronic coronary artery disease: the IACT Study. J Am Coll Cardiol 2005;46:1651-8.
40. Fuchs S, Kornowski R, Weisz G, Satler LF, Smits PC, Okubagzi P, Baffour R, Aggarwal A, Weissman NJ, Cerqueira M, Waks-man R, Serrruys P, Battler A, Moses JW, Leon MB, Epstein SE. Safety and feasibility of transendocardial autologous bone marrow cell transplantation in patients with advanced heart disease. Am J Cardiol 2006;97:823-9.
41. Fuchs S, Satler LF, Kornowski R, Okubagzi P, Weisz G, Baffour R, Waksman R, Weissman NJ, Cerqueira M, Leon MB, Epstein SE. Catheter-based autologous bone marrow myocardial in-jection in no-option patients with advanced coronary artery disease: a feasibility study. J Am Coll Cardiol 2003;41:1721-4.
42. Perin EC, Dohmann HF, Borojevic R, Silva SA, Sousa AL, Mes-quita CT, Rossi MI, Carvalho AC, Dutra HS, Dohmann HJ, Silva GV, Belem L, Vivacqua R, Rangel FO, Esporcatte R, Geng YJ, Vaughn WK, Assad JA, Mesquita ET, Willerson JT. Transendo-cardial, autologous bone marrow cell transplantation for se-vere, chronic ischemic heart failure. Circulation 2003;107:2294-302.
43. Perin EC, Dohmann HF, Borojevic R, Silva SA, Sousa AL, Silva GV, Mesquita CT, Belem L, Vaughn WK, Rangel FO, Assad JA, Carvalho AC, Branco RV, Rossi MI, Dohmann HJ, Willerson JT. Improved exercise capacity and ischemia 6 and 12 months after transendocardial injection of autologous bone marrow mononuclear cells for ischemic cardiomyopathy. Circulation 2004;110:II213-II218.
44. Strauer BE, Brehm M, Zeus T, Kostering M, Hernandez A, Sorg RV, Kogler G, Wernet P. Repair of infarcted myocardium by autologous intracoronary mononuclear bone marrow cell transplantation in humans. Circulation 2002;106:1913-8.
45. Stamm C, Westphal B, Kleine HD, Petzsch M, Kittner C, Klinge H, Schumichen C, Nienaber CA, Freund M, Steinhoff G. Auto-logous bone-marrow stem-cell transplantation for myocardi-al regeneration. Lancet 2003;361:45-6.
46. Assmus B, Schächinger V, Teupe C, Britten M, Lehmann R, Dobert N, Grunwald F, Aicher A, Urbich C, Martin H, Hoelzer D, Dimmeler S, Zeiher AM. Transplantation of Progenitor Cells and Regeneration Enhancement in Acute Myocardial In-farction (TOPCARE-AMI). Circulation 2002;106:3009-17.
47. Schächinger V, Assmus B, Britten MB, Honold J, Lehmann R, Teupe C, Abolmaali ND, Vogl TJ, Hofmann WK, Martin H, Dimmeler S, Zeiher AM. Transplantation of progenitor cells and regeneration enhancement in acute myocardial infarc-tion: final one-year results of the TOPCARE-AMI Trial. J Am Coll Cardiol 2004;44:1690-9.
48. Wollert KC, Meyer GP, Lotz J, Ringes-Lichtenberg S, Lippolt P, Breidenbach C, Fichtner S, Korte T, Hornig B, Messinger D, Arseniev L, Hertenstein B, Ganser A, Drexler H. Intracoronary autologous bone-marrow cell transfer after myocardial in-farction: the BOOST randomised controlled clinical trial. Lan-cet 2004;364:141-8.
49. Fernandez-Aviles F, San Roman JA, Garcia-Frade J, Fernandez ME, Penarrubia MJ, de la FL, Gomez-Bueno M, Cantalapiedra A, Fernandez J, Gutierrez O, Sanchez PL, Hernandez C, Sanz R, Garcia-Sancho J, Sanchez A. Experimental and clinical re-generative capability of human bone marrow cells after myocardial infarction. Circ Res 2004;95:742-8.
50. Schächinger V, Erbs S, Elsasser A, Haberbosch W, Hambrecht R, Holschermann H, Yu J, Corti R, Mathey DG, Hamm CW, Su-selbeck T, Assmus B, Tonn T, Dimmeler S, Zeiher AM. Intraco-ronary bone marrow-derived progenitor cells in acute myo-cardial infarction. N Engl J Med 2006;355:1210-21.
51. Lunde K, Solheim S, Aakhus S, Arnesen H, Abdelnoor M, Egeland T, Endresen K, Ilebekk A, Mangschau A, Fjeld JG, Smith HJ, Taraldsrud E, Grogaard HK, Bjornerheim R, Brekke M, Muller C, Hopp E, Ragnarsson A, Brinchmann JE, Forfang K. Intracoronary injection of mononuclear bone marrow cells in acute myocardial infarction. N Engl J Med 2006;355:1199-209.
52. Janssens S, Dubois C, Bogaert J, Theunissen K, Deroose C, Desmet W, Kalantzi M, Herbots L, Sinnaeve P, Dens J, Maer-tens J, Rademakers F, Dymarkowski S, Gheysens O, Van Cleemput J, Bormans G, Nuyts J, Belmans A, Mortelmans L, Boogaerts M, Van de WF. Autologous bone marrow-derived stem-cell transfer in patients with ST-segment elevation myocardial infarction: double-blind, randomised controlled trial. Lancet 2006;367:113-21.
53. Tendera M, Wojakowski W, Ruzyllo W, Chojnowska L, Kepka C, Tracz W, Musialek P, Piwowarska W, Nessler J, Buszman P, Grajek S, Breborowicz P, Majka M, Ratajczak MZ. Intracoro-nary infusion of bone marrow-derived selected CD34+CXCR4+ cells and non-selected mononuclear cells in patients with acute STEMI and reduced left ventricular ejec-tion fraction: results of randomized, multicentre Myocardial Regeneration by Intracoronary Infusion of Selected Popula-tion of Stem Cells in Acute Myocardial Infarction (REGENT) Trial. Eur Heart J 2009;30:1313-21.
54. Hirsch A, Nijveldt R, van d, V, Tijssen JG, van der Giessen WJ, Tio RA, Waltenberger J, Ten Berg JM, Doevendans PA, Aen-gevaeren WR, Zwaginga JJ, Biemond BJ, van Rossum AC, Piek JJ, Zijlstra F. Intracoronary Infusion of Mononuclear Cells From Bone Marrow or Peripheral Blood Compared With Standard Therapy in Patients After Acute Myocardial Infarc-tion Treated by Primary Percutaneous Coronary Interven-tion: Results of the Randomized Controlled HEBE Trial. Eur Heart J In press 2010.
55. Schächinger V, Erbs S, Elsasser A, Haberbosch W, Hambrecht R, Holschermann H, Yu J, Corti R, Mathey DG, Hamm CW, Su-selbeck T, Werner N, Haase J, Neuzner J, Germing A, Mark B, Assmus B, Tonn T, Dimmeler S, Zeiher AM. Improved clinical outcome after intracoronary administration of bone-marrow-derived progenitor cells in acute myocardial infarc-tion: final 1-year results of the REPAIR-AMI trial. Eur Heart J 2006;27:2775-83.
56. Assmus B, Rolf A, Erbs S, Elsasser A, Haberbosch W, Ham-brecht R, Tillmanns H, Yu J, Corti R, Mathey DG, Hamm CW, Suselbeck T, Tonn T, Dimmeler S, Dill T, Zeiher AM, Scha-chinger V. Clinical outcome 2 years after intracoronary ad-ministration of bone marrow-derived progenitor cells in acute myocardial infarction. Circ Heart Fail 2010;3:89-96.
57. Meyer GP, Wollert KC, Lotz J, Steffens J, Lippolt P, Fichtner S, Hecker H, Schaefer A, Arseniev L, Hertenstein B, Ganser A, Drexler H. Intracoronary bone marrow cell transfer after myocardial infarction: eighteen months' follow-up data from the randomized, controlled BOOST (BOne marrOw transfer to enhance ST-elevation infarct regeneration) trial. Circula-tion 2006;113:1287-94.
58. Erbs S, Linke A, Schachinger V, Assmus B, Thiele H, Diederich KW, Hoffmann C, Dimmeler S, Tonn T, Hambrecht R, Zeiher AM, Schuler G. Restoration of microvascular function in the infarct-related artery by intracoronary transplantation of bone marrow progenitor cells in patients with acute myocar-dial infarction: the Doppler Substudy of the Reinfusion of Enriched Progenitor Cells and Infarct Remodeling in Acute Myocardial Infarction (REPAIR-AMI) trial. Circulation 2007;116:366-74.
59. van Ramshorst J., Bax JJ, Beeres SL, Abbets-Schneider P, Roes SD, Stokkel MP, de RA, Fibbe WE, Zwaginga JJ, Boersma E, Schalij MJ, Atsma DE. Intramyocardial bone marrow cell in-jection for chronic myocardial ischemia: a randomized con-trolled trial. JAMA 2009;301:1997-2004.
60. Ripa RS, Wang Y, Jørgensen E, Kastrup J. [Therapy with stem cells for acute ischemic heart disease: myocardial regenera-tion?]. Ugeskr Laeger 2007;169:119-22.
61. Johnsen HE. Clinical practice and future needs in recombi-nant human granulocyte colony-stimulating factor treat-ment: a review of randomized trials in clinical haemato-oncology. J Int Med Res 2001;29:87-99.
62. Avalos BR. Molecular analysis of the granulocyte colony-stimulating factor receptor. Blood 1996;88:761-77.
63. Dong F, Larner AC. Activation of Akt kinase by granulocyte colony-stimulating factor (G-CSF): evidence for the role of a tyrosine kinase activity distinct from the Janus kinases. Blood 2000;95:1656-62.
64. Anderlini P, Donato M, Chan KW, Huh YO, Gee AP, Lauppe MJ, Champlin RE, Korbling M. Allogeneic blood progenitor cell collection in normal donors after mobilization with fil-grastim: the M.D. Anderson Cancer Center experience. Transfusion 1999;39:555-60.
65. Nagasawa T, Kikutani H, Kishimoto T. Molecular cloning and structure of a pre-B-cell growth-stimulating factor. Proc Natl Acad Sci U S A 1994;91:2305-9.
66. Deichmann M, Kronenwett R, Haas R. Expression of the human immunodeficiency virus type-1 coreceptors CXCR-4 (fusin, LESTR) and CKR-5 in CD34+ hematopoietic progenitor cells. Blood 1997;89:3522-8.
67. Petit I, Szyper-Kravitz M, Nagler A, Lahav M, Peled A, Habler L, Ponomaryov T, Taichman RS, renzana-Seisdedos F, Fujii N, Sandbank J, Zipori D, Lapidot T. G-CSF induces stem cell mo-bilization by decreasing bone marrow SDF-1 and up-regulating CXCR4. Nat Immunol 2002;3:687-94.
68. Semerad CL, Christopher MJ, Liu F, Short B, Simmons PJ, Winkler I, Levesque JP, Chappel J, Ross FP, Link DC. G-CSF po-tently inhibits osteoblast activity and CXCL12 mRNA expres-sion in the bone marrow. Blood 2005;106:3020-7.
69. Kawabata K, Ujikawa M, Egawa T, Kawamoto H, Tachibana K, Iizasa H, Katsura Y, Kishimoto T, Nagasawa T. A cell-autonomous requirement for CXCR4 in long-term lymphoid and myeloid reconstitution. Proc Natl Acad Sci U S A 1999;96:5663-7.
70. Flomenberg N, DiPersio J, Calandra G. Role of CXCR4 chemo-kine receptor blockade using AMD3100 for mobilization of autologous hematopoietic progenitor cells. Acta Haematol 2005;114:198-205.
71. Nervi B, Link DC, DiPersio JF. Cytokines and hematopoietic stem cell mobilization. J Cell Biochem 2006;99:690-705.
72. Levesque JP, Hendy J, Takamatsu Y, Williams B, Winkler IG, Simmons PJ. Mobilization by either cyclophosphamide or granulocyte colony-stimulating factor transforms the bone marrow into a highly proteolytic environment. Exp Hematol 2002;30:440-9.
73. Levesque JP, Takamatsu Y, Nilsson SK, Haylock DN, Simmons PJ. Vascular cell adhesion molecule-1 (CD106) is cleaved by neutrophil proteases in the bone marrow following hemato-poietic progenitor cell mobilization by granulocyte colony-stimulating factor. Blood 2001;98:1289-97.
74. Heissig B, Hattori K, Dias S, Friedrich M, Ferris B, Hackett NR, Crystal RG, Besmer P, Lyden D, Moore MA, Werb Z, Rafii S. Recruitment of stem and progenitor cells from the bone marrow niche requires MMP-9 mediated release of kit-ligand. Cell 2002;109:625-37.
75. Levesque JP, Liu F, Simmons PJ, Betsuyaku T, Senior RM, Pham C, Link DC. Characterization of hematopoietic progeni-tor mobilization in protease-deficient mice. Blood 2004;104:65-72.
76. Harada M, Qin Y, Takano H, Minamino T, Zou Y, Toko H, Ohtsuka M, Matsuura K, Sano M, Nishi J, Iwanaga K, Akazawa H, Kunieda T, Zhu W, Hasegawa H, Kunisada K, Nagai T, Na-kaya H, Yamauchi-Takihara K, Komuro I. G-CSF prevents car-diac remodeling after myocardial infarction by activating the Jak-Stat pathway in cardiomyocytes. Nat Med 2005;11:305-11.
77. Hilfiker-Kleiner D, Hilfiker A, Fuchs M, Kaminski K, Schaefer A, Schieffer B, Hillmer A, Schmiedl A, Ding Z, Podewski E, Po-dewski E, Poli V, Schneider MD, Schulz R, Park JK, Wollert KC, Drexler H. Signal transducer and activator of transcription 3 is required for myocardial capillary growth, control of inters-titial matrix deposition, and heart protection from ischemic injury. Circ Res 2004;95:187-95.
78. Yamauchi-Takihara K, Kishimoto T. A novel role for STAT3 in cardiac remodeling. Trends Cardiovasc Med 2000;10:298-303.
79. Ueda K, Takano H, Hasegawa H, Niitsuma Y, Qin Y, Ohtsuka M, Komuro I. Granulocyte colony stimulating factor directly inhibits myocardial ischemia-reperfusion injury through Akt-endothelial NO synthase pathway. Arterioscler Thromb Vasc Biol 2006;26:e108-e113.
80. Boneberg EM, Hareng L, Gantner F, Wendel A, Hartung T. Human monocytes express functional receptors for granulo-cyte colony-stimulating factor that mediate suppression of monokines and interferon-gamma. Blood 2000;95:270-6.
81. Hartung T. Anti-inflammatory effects of granulocyte colony-stimulating factor. Curr Opin Hematol 1998;5:221-5.
82. Misao Y, Takemura G, Arai M, Ohno T, Onogi H, Takahashi T, Minatoguchi S, Fujiwara T, Fujiwara H. Importance of re-cruitment of bone marrow-derived CXCR4+ cells in post-infarct cardiac repair mediated by G-CSF. Cardiovasc Res 2006;71:455-65.
83. Anderlini P, Przepiorka D, Seong D, Miller P, Sundberg J, Lichtiger B, Norfleet F, Chan KW, Champlin R, Korbling M. Clinical toxicity and laboratory effects of granulocyte-colony-stimulating factor (filgrastim) mobilization and blood stem cell apheresis from normal donors, and analysis of charges for the procedures. Transfusion 1996;36:590-5.
84. Cavallaro AM, Lilleby K, Majolino I, Storb R, Appelbaum FR, Rowley SD, Bensinger WI. Three to six year follow-up of normal donors who received recombinant human granulo-cyte colony-stimulating factor. Bone Marrow Transplant 2000;25:85-9.
85. Carmeliet P. Mechanisms of angiogenesis and arteriogenesis. Nat Med 2000;6:389-95.
86. Lancrin C, Sroczynska P, Stephenson C, Allen T, Kouskoff V, Lacaud G. The haemangioblast generates haematopoietic cells through a haemogenic endothelium stage. Nature 2009;457:892-5.
87. Ferguson JE, III, Kelley RW, Patterson C. Mechanisms of endothelial differentiation in embryonic vasculogenesis. Ar-terioscler Thromb Vasc Biol 2005;25:2246-54.
88. McGrath KE, Koniski AD, Maltby KM, McGann JK, Palis J. Embryonic expression and function of the chemokine SDF-1 and its receptor, CXCR4. Dev Biol 1999;213:442-56.
89. Cox CM, Poole TJ. Angioblast differentiation is influenced by the local environment: FGF-2 induces angioblasts and pat-terns vessel formation in the quail embryo. Dev Dyn 2000;218:371-82.
90. Carmeliet P, Ferreira V, Breier G, Pollefeyt S, Kieckens L, Gertsenstein M, Fahrig M, Vandenhoeck A, Harpal K, Eber-hardt C, Declercq C, Pawling J, Moons L, Collen D, Risau W, Nagy A. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 1996;380:435-9.
91. Tomanek RJ, Christensen LP, Simons M, Murakami M, Zheng W, Schatteman GC. Embryonic coronary vasculogenesis and angiogenesis are regulated by interactions between multiple FGFs and VEGF and are influenced by mesenchymal stem cells. Dev Dyn 2010;239:3182-91.
92. Takahashi T, Kalka C, Masuda H, Chen D, Silver M, Kearney M, Magner M, Isner JM, Asahara T. Ischemia-and cytokine-induced mobilization of bone marrow-derived endothelial progenitor cells for neovascularization. Nat Med 1999;5:434-8.
93. Asahara T, Takahashi T, Masuda H, Kalka C, Chen D, Iwaguro H, Inai Y, Silver M, Isner JM. VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived en-dothelial progenitor cells. EMBO J 1999;18:3964-72.
94. Hattori K, Dias S, Heissig B, Hackett NR, Lyden D, Tateno M, Hicklin DJ, Zhu Z, Witte L, Crystal RG, Moore MA, Rafii S. Vas-cular endothelial growth factor and angiopoietin-1 stimulate postnatal hematopoiesis by recruitment of vasculogenic and hematopoietic stem cells. J Exp Med 2001;193:1005-14.
95. Ceradini DJ, Kulkarni AR, Callaghan MJ, Tepper OM, Bastidas N, Kleinman ME, Capla JM, Galiano RD, Levine JP, Gurtner GC. Progenitor cell trafficking is regulated by hypoxic gra-dients through HIF-1 induction of SDF-1. Nat Med 2004;10:858-64.
96. Kaelin WG, Jr., Ratcliffe PJ. Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway. Mol Cell 2008;30:393-402.
97. Kelly BD, Hackett SF, Hirota K, Oshima Y, Cai Z, Berg-Dixon S, Rowan A, Yan Z, Campochiaro PA, Semenza GL. Cell type-specific regulation of angiogenic growth factor gene expres-sion and induction of angiogenesis in nonischemic tissue by a constitutively active form of hypoxia-inducible factor 1. Circ Res 2003;93:1074-81.
98. Ruhrberg C, Gerhardt H, Golding M, Watson R, Ioannidou S, Fujisawa H, Betsholtz C, Shima DT. Spatially restricted pat-terning cues provided by heparin-binding VEGF-A control blood vessel branching morphogenesis. Genes Dev 2002;16:2684-98.
99. Gerhardt H, Golding M, Fruttiger M, Ruhrberg C, Lundkvist A, Abramsson A, Jeltsch M, Mitchell C, Alitalo K, Shima D, Bet-sholtz C. VEGF guides angiogenic sprouting utilizing endo-thelial tip cell filopodia. J Cell Biol 2003;161:1163-77.
100. Hellstrom M, Phng LK, Hofmann JJ, Wallgard E, Coultas L, Lindblom P, Alva J, Nilsson AK, Karlsson L, Gaiano N, Yoon K, Rossant J, Iruela-Arispe ML, Kalen M, Gerhardt H, Betsholtz C. Dll4 signalling through Notch1 regulates formation of tip cells during angiogenesis. Nature 2007;445:776-80.
101. Yana I, Sagara H, Takaki S, Takatsu K, Nakamura K, Nakao K, Katsuki M, Taniguchi S, Aoki T, Sato H, Weiss SJ, Seiki M. Crosstalk between neovessels and mural cells directs the site-specific expression of MT1-MMP to endothelial tip cells. J Cell Sci 2007;120:1607-14.
102. Fantin A, Vieira JM, Gestri G, Denti L, Schwarz Q, Prykhozhij S, Peri F, Wilson SW, Ruhrberg C. Tissue macrophages act as cellular chaperones for vascular anastomosis downstream of VEGF-mediated endothelial tip cell induction. Blood 2010;116:829-40.
103. Demicheva E, Hecker M, Korff T. Stretch-induced activation of the transcription factor activator protein-1 controls mo-nocyte chemoattractant protein-1 expression during arteri-ogenesis. Circ Res 2008;103:477-84.
104. Garcia-Cardena G, Comander J, Anderson KR, Blackman BR, Gimbrone MA, Jr. Biomechanical activation of vascular endo-thelium as a determinant of its functional phenotype. Proc Natl Acad Sci U S A 2001;98:4478-85.
105. Lee CW, Stabile E, Kinnaird T, Shou M, Devaney JM, Epstein SE, Burnett MS. Temporal patterns of gene expression after acute hindlimb ischemia in mice: insights into the genomic program for collateral vessel development. J Am Coll Cardiol 2004;43:474-82.
106. Scholz D, Ito W, Fleming I, Deindl E, Sauer A, Wiesnet M, Busse R, Schaper J, Schaper W. Ultrastructure and molecular histology of rabbit hind-limb collateral artery growth (arteri-ogenesis). Virchows Arch 2000;436:257-70.
107. Cai W, Vosschulte R, fsah-Hedjri A, Koltai S, Kocsis E, Scholz D, Kostin S, Schaper W, Schaper J. Altered balance between extracellular proteolysis and antiproteolysis is associated with adaptive coronary arteriogenesis. J Mol Cell Cardiol 2000;32:997-1011.
108. Wu S, Wu X, Zhu W, Cai WJ, Schaper J, Schaper W. Immuno-histochemical study of the growth factors, aFGF, bFGF, PDGF-AB, VEGF-A and its receptor (Flk-1) during arteriogene-sis. Mol Cell Biochem 2010;343:223-9.
109. Kinnaird T, Stabile E, Burnett MS, Lee CW, Barr S, Fuchs S, Epstein SE. Marrow-derived stromal cells express genes en-coding a broad spectrum of arteriogenic cytokines and pro-mote in vitro and in vivo arteriogenesis through paracrine mechanisms. Circ Res 2004;94:678-85.
110. Hoefer IE, van RN, Buschmann IR, Piek JJ, Schaper W. Time course of arteriogenesis following femoral artery occlusion in the rabbit. Cardiovasc Res 2001;49:609-17.
111. Behm CZ, Kaufmann BA, Carr C, Lankford M, Sanders JM, Rose CE, Kaul S, Lindner JR. Molecular imaging of endothelial vascular cell adhesion molecule-1 expression and inflamma-tory cell recruitment during vasculogenesis and ischemia-mediated arteriogenesis. Circulation 2008;117:2902-11.
112. Soehnlein O, Zernecke A, Eriksson EE, Rothfuchs AG, Pham CT, Herwald H, Bidzhekov K, Rottenberg ME, Weber C, Lind-bom L. Neutrophil secretion products pave the way for in-flammatory monocytes. Blood 2008;112:1461-71.
113. Bergmann CE, Hoefer IE, Meder B, Roth H, van RN, Breit SM, Jost MM, Aharinejad S, Hartmann S, Buschmann IR. Arteri-ogenesis depends on circulating monocytes and macrophage accumulation and is severely depressed in op/op mice. J Leukoc Biol 2006;80:59-65.
114. Bakker EN, Matlung HL, Bonta P, de Vries CJ, van RN, Vanba-vel E. Blood flow-dependent arterial remodelling is facilitated by inflammation but directed by vascular tone. Cardiovasc Res 2008;78:341-8.
115. Khmelewski E, Becker A, Meinertz T, Ito WD. Tissue resident cells play a dominant role in arteriogenesis and concomitant macrophage accumulation. Circ Res 2004;95:E56-E64.
116. Aicher A, Rentsch M, Sasaki K, Ellwart JW, Fandrich F, Siebert R, Cooke JP, Dimmeler S, Heeschen C. Nonbone marrow-derived circulating progenitor cells contribute to postnatal neovascularization following tissue ischemia. Circ Res 2007;100:581-9.
117. Tepper OM, Capla JM, Galiano RD, Ceradini DJ, Callaghan MJ, Kleinman ME, Gurtner GC. Adult vasculogenesis occurs through in situ recruitment, proliferation, and tubulization of circulating bone marrow-derived cells. Blood 2005;105:1068-77.
118. Reinecke H, Minami E, Zhu WZ, Laflamme MA. Cardiogenic differentiation and transdifferentiation of progenitor cells. Circ Res 2008;103:1058-71.
119. Copelan EA. Hematopoietic stem-cell transplantation. N Engl J Med 2006;354:1813-26.
120. Shpall EJ, Champlin R, Glaspy JA. Effect of CD34+ peripheral blood progenitor cell dose on hematopoietic recovery. Biol Blood Marrow Transplant 1998;4:84-92.
121. Rota M, Kajstura J, Hosoda T, Bearzi C, Vitale S, Esposito G, Iaffaldano G, Padin-Iruegas ME, Gonzalez A, Rizzi R, Small N, Muraski J, Alvarez R, Chen X, Urbanek K, Bolli R, Houser SR, Leri A, Sussman MA, Anversa P. Bone marrow cells adopt the cardiomyogenic fate in vivo. Proc Natl Acad Sci U S A 2007;104:17783-8.
122. Balsam LB, Wagers AJ, Christensen JL, Kofidis T, Weissman IL, Robbins RC. Haematopoietic stem cells adopt mature hae-matopoietic fates in ischaemic myocardium. Nature 2004;428:668-73.
123. Richardson MR, Yoder MC. Endothelial progenitor cells: Quo Vadis? J Mol Cell Cardiol 2011;50:266-72.
124. Timmermans F, Van HF, De SM, Raedt R, Plasschaert F, De Buyzere ML, Gillebert TC, Plum J, Vandekerckhove B. Endo-thelial outgrowth cells are not derived from CD133+ cells or CD45+ hematopoietic precursors. Arterioscler Thromb Vasc Biol 2007;27:1572-9.
125. Massa M, Rosti V, Ferrario M, Campanelli R, Ramajoli I, Rosso R, De Ferrari GM, Ferlini M, Goffredo L, Bertoletti A, Klersy C, Pecci A, Moratti R, Tavazzi L. Increased circulating hemato-poietic and endothelial progenitor cells in the early phase of acute myocardial infarction. Blood 2005;105:199-206.
126. Kunz GA, Liang G, Cuculi F, Gregg D, Vata KC, Shaw LK, Gold-schmidt-Clermont PJ, Dong C, Taylor DA, Peterson ED. Circu-lating endothelial progenitor cells predict coronary artery disease severity. Am Heart J 2006;152:190-5.
127. Wang CH, Verma S, Hsieh IC, Chen YJ, Kuo LT, Yang NI, Wang SY, Wu MY, Hsu CM, Cheng CW, Cherng WJ. Enalapril in-creases ischemia-induced endothelial progenitor cell mobili-zation through manipulation of the CD26 system. J Mol Cell Cardiol 2006;41:34-43.
128. Vasa M, Fichtlscherer S, Adler K, Aicher A, Martin H, Zeiher AM, Dimmeler S. Increase in circulating endothelial progeni-tor cells by statin therapy in patients with stable coronary ar-tery disease. Circulation 2001;103:2885-90.
129. Shi Q, Rafii S, Wu MH, Wijelath ES, Yu C, Ishida A, Fujita Y, Kothari S, Mohle R, Sauvage LR, Moore MA, Storb RF, Ham-mond WP. Evidence for circulating bone marrow-derived en-dothelial cells. Blood 1998;92:362-7.
130. Urbich C, Aicher A, Heeschen C, Dernbach E, Hofmann WK, Zeiher AM, Dimmeler S. Soluble factors released by endo-thelial progenitor cells promote migration of endothelial cells and cardiac resident progenitor cells. J Mol Cell Cardiol 2005;39:733-42.
131. Badorff C, Brandes RP, Popp R, Rupp S, Urbich C, Aicher A, Fleming I, Busse R, Zeiher AM, Dimmeler S. Transdifferentia-tion of blood-derived human adult endothelial progenitor cells into functionally active cardiomyocytes. Circulation 2003;107:1024-32.
132. Koyanagi M, Urbich C, Chavakis E, Hoffmann J, Rupp S, Ba-dorff C, Zeiher AM, Starzinski-Powitz A, Haendeler J, Dimme-ler S. Differentiation of circulating endothelial progenitor cells to a cardiomyogenic phenotype depends on E-cadherin. FEBS Lett 2005;579:6060-6.
133. Gruh I, Beilner J, Blomer U, Schmiedl A, Schmidt-Richter I, Kruse ML, Haverich A, Martin U. No evidence of transdiffe-rentiation of human endothelial progenitor cells into cardi-omyocytes after coculture with neonatal rat cardiomyocytes. Circulation 2006;113:1326-34.
134. Friedenstein AJ, Chailakhyan RK, Latsinik NV, Panasyuk AF, Keiliss-Borok IV. Stromal cells responsible for transferring the microenvironment of the hemopoietic tissues. Cloning in vitro tro and retransplantation in vivo. Transplantation 1974;17:331-40.
135. Jiang Y, Jahagirdar BN, Reinhardt RL, Schwartz RE, Keene CD, Ortiz-Gonzalez XR, Reyes M, Lenvik T, Lund T, Blackstad M, Du J, Aldrich S, Lisberg A, Low WC, Largaespada DA, Verfaillie CM. Pluripotency of mesenchymal stem cells derived from adult marrow. Nature 2002;418:41-9.
136. Reyes M, Verfaillie CM. Characterization of multipotent adult progenitor cells, a subpopulation of mesenchymal stem cells. Ann N Y Acad Sci 2001;938:231-3.
137. Porada CD, meida-Porada G. Mesenchymal stem cells as therapeutics and vehicles for gene and drug delivery. Adv Drug Deliv Rev 2010;62:1156-66.
138. Crisan M, Yap S, Casteilla L, Chen CW, Corselli M, Park TS, Andriolo G, Sun B, Zheng B, Zhang L, Norotte C, Teng PN, Traas J, Schugar R, Deasy BM, Badylak S, Buhring HJ, Giaco-bino JP, Lazzari L, Huard J, Peault B. A perivascular origin for mesenchymal stem cells in multiple human organs. Cell Stem Cell 2008;3:301-13.
139. Corselli M, Chen CW, Crisan M, Lazzari L, Peault B. Perivascu-lar ancestors of adult multipotent stem cells. Arterioscler Thromb Vasc Biol 2010;30:1104-9.
140. Rojewski M, Weber B, Schrezenmeier H. Phenotypic Charac-terization of Mesenchymal Stem Cells from Various Tissues. Transfus Med Hemother 2008;35:168-84.
141. Dominici M, Le BK, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, Deans R, Keating A, Prockop D, Horwitz E. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 2006;8:315-7.
142. Horwitz EM, Le BK, Dominici M, Mueller I, Slaper-Cortenbach I, Marini FC, Deans RJ, Krause DS, Keating A. Clarification of the nomenclature for MSC: The International Society for Cel-lular Therapy position statement. Cytotherapy 2005;7:393-5.
143. Wu X, Huang L, Zhou Q, Song Y, Li A, Jin J, Cui B. Mesen-chymal stem cells participating in ex vivo endothelium repair and its effect on vascular smooth muscle cells growth. Int J Cardiol 2005;105:274-82.
144. Oswald J, Boxberger S, Jorgensen B, Feldmann S, Ehninger G, Bornhauser M, Werner C. Mesenchymal stem cells can be differentiated into endothelial cells in vitro. Stem Cells 2004;22:377-84.
145. Ball SG, Shuttleworth AC, Kielty CM. Direct cell contact influ-ences bone marrow mesenchymal stem cell fate. Int J Bio-chem Cell Biol 2004;36:714-27.
146. Toma C, Pittenger MF, Cahill KS, Byrne BJ, Kessler PD. Human mesenchymal stem cells differentiate to a cardiomyocyte phenotype in the adult murine heart. Circulation 2002;105:93-8.
147. Tokcaer-Keskin Z, Akar AR, yaloglu-Butun F, Terzioglu-Kara E, Durdu S, Ozyurda U, Ugur M, Akcali KC. Timing of induction of cardiomyocyte differentiation for in vitro cultured mesen-chymal stem cells: a perspective for emergencies. Can J Phy-siol Pharmacol 2009;87:143-50.
148. Dai W, Hale SL, Martin BJ, Kuang JQ, Dow JS, Wold LE, Kloner RA. Allogeneic Mesenchymal Stem Cell Transplantation in Postinfarcted Rat Myocardium: Short-and Long-Term Ef-fects. Circulation 2005;112:214-23.
149. Iso Y, Spees JL, Serrano C, Bakondi B, Pochampally R, Song YH, Sobel BE, Delafontaine P, Prockop DJ. Multipotent hu-man stromal cells improve cardiac function after myocardial infarction in mice without long-term engraftment. Biochem Biophys Res Commun 2007;354:700-6.
150. Sadat S, Gehmert S, Song YH, Yen Y, Bai X, Gaiser S, Klein H, Alt E. The cardioprotective effect of mesenchymal stem cells is mediated by IGF-I and VEGF. Biochem Biophys Res Com-mun 2007;363:674-9.
151. Honczarenko M, Le Y, Swierkowski M, Ghiran I, Glodek AM, Silberstein LE. Human bone marrow stromal cells express a distinct set of biologically functional chemokine receptors. Stem Cells 2006;24:1030-41.
152. Von L, I, Notohamiprodjo M, Wechselberger A, Peters C, Henger A, Seliger C, Djafarzadeh R, Huss R, Nelson PJ. Human adult CD34-progenitor cells functionally express the chemo-kine receptors CCR1, CCR4, CCR7, CXCR5, and CCR10 but not CXCR4. Stem Cells Dev 2005;14:329-36.
153. Barbash IM, Chouraqui P, Baron J, Feinberg MS, Etzion S, Tessone A, Miller L, Guetta E, Zipori D, Kedes LH, Kloner RA, Leor J. Systemic delivery of bone marrow-derived mesen-chymal stem cells to the infarcted myocardium: feasibility, cell migration, and body distribution. Circulation 2003;108:863-8.
154. Morigi M, Imberti B, Zoja C, Corna D, Tomasoni S, Abbate M, Rottoli D, Angioletti S, Benigni A, Perico N, Alison M, Remuzzi G. Mesenchymal stem cells are renotropic, helping to repair the kidney and improve function in acute renal failure. J Am Soc Nephrol 2004;15:1794-804.
155. Granero-Molto F, Weis JA, Miga MI, Landis B, Myers TJ, O'Rear L, Longobardi L, Jansen ED, Mortlock DP, Spagnoli A. Regenerative effects of transplanted mesenchymal stem cells in fracture healing. Stem Cells 2009;27:1887-98.
156. Ruster B, Gottig S, Ludwig RJ, Bistrian R, Muller S, Seifried E, Gille J, Henschler R. Mesenchymal stem cells display coordi-nated rolling and adhesion behavior on endothelial cells. Blood 2006;108:3938-44.
157. Cheng Z, Ou L, Zhou X, Li F, Jia X, Zhang Y, Liu X, Li Y, Ward CA, Melo LG, Kong D. Targeted migration of mesenchymal stem cells modified with CXCR4 gene to infarcted myocar-dium improves cardiac performance. Mol Ther 2008;16:571-9.
158. Cho HH, Kyoung KM, Seo MJ, Kim YJ, Bae YC, Jung JS. Over-expression of CXCR4 increases migration and proliferation of human adipose tissue stromal cells. Stem Cells Dev 2006;15:853-64.
159. Ip JE, Wu Y, Huang J, Zhang L, Pratt RE, Dzau VJ. Mesen-chymal stem cells use integrin beta1 not CXC chemokine re-ceptor 4 for myocardial migration and engraftment. Mol Biol Cell 2007;18:2873-82.
160. Schenk S, Mal N, Finan A, Zhang M, Kiedrowski M, Popovic Z, McCarthy PM, Penn MS. Monocyte chemotactic protein-3 is a myocardial mesenchymal stem cell homing factor. Stem Cells 2007;25:245-51.
161. Silva GV, Litovsky S, Assad JA, Sousa AL, Martin BJ, Vela D, Coulter SC, Lin J, Ober J, Vaughn WK, Branco RV, Oliveira EM, He R, Geng YJ, Willerson JT, Perin EC. Mesenchymal stem cells differentiate into an endothelial phenotype, enhance vascular density, and improve heart function in a canine chronic ischemia model. Circulation 2005;111:150-6.
162. Shake JG, Gruber PJ, Baumgartner WA, Senechal G, Meyers J, Redmond JM, Pittenger MF, Martin BJ. Mesenchymal stem cell implantation in a swine myocardial infarct model: en-graftment and functional effects. Ann Thorac Surg 2002;73:1919-25.
163. Amado LC, Saliaris AP, Schuleri KH, St JM, Xie JS, Cattaneo S, Durand DJ, Fitton T, Kuang JQ, Stewart G, Lehrke S, Baum-gartner WW, Martin BJ, Heldman AW, Hare JM. Cardiac repair with intramyocardial injection of allogeneic mesen-chymal stem cells after myocardial infarction. Proc Natl Acad Sci U S A 2005;102:11474-9.
164. Miyahara Y, Nagaya N, Kataoka M, Yanagawa B, Tanaka K, Hao H, Ishino K, Ishida H, Shimizu T, Kangawa K, Sano S, Oka-no T, Kitamura S, Mori H. Monolayered mesenchymal stem cells repair scarred myocardium after myocardial infarction. Nat Med 2006;12:459-65.
165. Ziegelhoeffer T, Fernandez B, Kostin S, Heil M, Voswinckel R, Helisch A, Schaper W. Bone marrow-derived cells do not in-corporate into the adult growing vasculature. Circ Res 2004;94:230-8.
166. Lee RH, Pulin AA, Seo MJ, Kota DJ, Ylostalo J, Larson BL, Semprun-Prieto L, Delafontaine P, Prockop DJ. Intravenous hMSCs improve myocardial infarction in mice because cells embolized in lung are activated to secrete the anti-inflammatory protein TSG-6. Cell Stem Cell 2009;5:54-63.
167. He Q, Wan C, Li G. Concise review: multipotent mesenchymal stromal cells in blood. Stem Cells 2007;25:69-77.
168. Kuznetsov SA, Mankani MH, Gronthos S, Satomura K, Bianco P, Robey PG. Circulating skeletal stem cells. J Cell Biol 2001;153:1133-40.
169. Tondreau T, Meuleman N, Delforge A, Dejeneffe M, Leroy R, Massy M, Mortier C, Bron D, Lagneaux L. Mesenchymal stem cells derived from CD133-positive cells in mobilized peri-pheral blood and cord blood: proliferation, Oct4 expression, and plasticity. Stem Cells 2005;23:1105-12.
170. Fernandez M, Simon V, Herrera G, Cao C, Del FH, Minguell JJ. Detection of stromal cells in peripheral blood progenitor cell collections from breast cancer patients. Bone Marrow Trans-plant 1997;20:265-71.
171. Wexler SA, Donaldson C, ning-Kendall P, Rice C, Bradley B, Hows JM. Adult bone marrow is a rich source of human me-senchymal /'stem/' cells but umbilical cord and mobilized adult blood are not. Br J Haematol 2003;121:368-74.
172. Lazarus HM, Haynesworth SE, Gerson SL, Caplan AI. Human bone marrow-derived mesenchymal stromal (progenitor cells MPCs) cannot be recovered from peripheral blood pro-genitor cell collections. J Hematother 1997;6:447-55.
173. Kassis I, Zangi L, Rivkin R, Levdansky L, Samuel S, Marx G, Gorodetsky R. Isolation of mesenchymal stem cells from G-CSF-mobilized human peripheral blood using fibrin micro-beads. Bone Marrow Transplant 2006;37:967-76.
174. Kawamoto A, Gwon HC, Iwaguro H, Yamaguchi JI, Uchida S, Masuda H, Silver M, Ma H, Kearney M, Isner JM, Asahara T. Therapeutic potential of ex vivo expanded endothelial pro-genitor cells for myocardial ischemia. Circulation 2001;103:634-7.
175. Oswald J, Boxberger S, Jorgensen B, Feldmann S, Ehninger G, Bornhauser M, Werner C. Mesenchymal stem cells can be differentiated into endothelial cells in vitro. Stem Cells 2004;22:377-84.
176. Yoon CH, Koyanagi M, Iekushi K, Seeger F, Urbich C, Zeiher AM, Dimmeler S. Mechanism of improved cardiac function after bone marrow mononuclear cell therapy: role of cardi-ovascular lineage commitment. Circulation 2010;121:2001-11.
177. Gnecchi M, Zhang Z, Ni A, Dzau VJ. Paracrine mechanisms in adult stem cell signaling and therapy. Circ Res 2008;103:1204-19.
178. Gnecchi M, He H, Liang OD, Melo LG, Morello F, Mu H, Noi-seux N, Zhang L, Pratt RE, Ingwall JS, Dzau VJ. Paracrine ac-tion accounts for marked protection of ischemic heart by Akt-modified mesenchymal stem cells. Nat Med 2005;11:367-8.
179. Takahashi M, Li TS, Suzuki R, Kobayashi T, Ito H, Ikeda Y, Matsuzaki M, Hamano K. Cytokines produced by bone mar-row cells can contribute to functional improvement of the in-farcted heart by protecting cardiomyocytes from ischemic in-jury. Am J Physiol Heart Circ Physiol 2006;291:H886-H893.
180. Maxeiner H, Krehbiehl N, Muller A, Woitasky N, Akinturk H, Muller M, Weigand MA, Abdallah Y, Kasseckert S, Schreck-enberg R, Schluter KD, Wenzel S. New insights into paracrine mechanisms of human cardiac progenitor cells. Eur J Heart Fail 2010;12:730-7.
181. Kinnaird T, Stabile E, Burnett MS, Shou M, Lee CW, Barr S, Fuchs S, Epstein SE. Local delivery of marrow-derived stromal cells augments collateral perfusion through paracrine me-chanisms. Circulation 2004;109:1543-9.
182. Shabbir A, Zisa D, Lin H, Mastri M, Roloff G, Suzuki G, Lee T. Activation of host tissue trophic factors through JAK-STAT3 signaling: a mechanism of mesenchymal stem cell-mediated cardiac repair. Am J Physiol Heart Circ Physiol 2010;299:H1428-H1438.
183. Lewis EF, Johnson PA, Johnson W, Collins C, Griffin L, Steven-son LW. Preferences for quality of life or survival expressed by patients with heart failure. J Heart Lung Transplant 2001;20:1016-24.
184. Sugeng L, Mor-Avi V, Weinert L, Niel J, Ebner C, Steringer-Mascherbauer R, Schmidt F, Galuschky C, Schummers G, Lang RM, Nesser HJ. Quantitative assessment of left ventri-cular size and function: side-by-side comparison of real-time three-dimensional echocardiography and computed tomo-graphy with magnetic resonance reference. Circulation 2006;114:654-61.
185. St John SM, Pfeffer MA, Plappert T, Rouleau JL, Moye LA, Dagenais GR, Lamas GA, Klein M, Sussex B, Goldman S,. Quantitative two-dimensional echocardiographic measure-ments are major predictors of adverse cardiovascular events after acute myocardial infarction. The protective effects of captopril. Circulation 1994;89:68-75.
186. Kjoller E, Kober L, Jorgensen S, Torp-Pedersen C. Long-term prognostic importance of hyperkinesia following acute myo-cardial infarction. TRACE Study Group. TRAndolapril Cardiac Evaluation. Am J Cardiol 1999;83:655-9.
187. Moller JE, Hillis GS, Oh JK, Reeder GS, Gersh BJ, Pellikka PA. Wall motion score index and ejection fraction for risk stratifi-cation after acute myocardial infarction. Am Heart J 2006;151:419-25.
188. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, Picard MH, Roman MJ, Seward J, Shanewise JS, Solomon SD, Spencer KT, Sutton MS, Stewart WJ. Recom-mendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writ-ing Group, developed in conjunction with the European As-sociation of Echocardiography, a branch of the European So-ciety of Cardiology. J Am Soc Echocardiogr 2005;18:1440-63.
189. McGowan JH, Cleland JG. Reliability of reporting left ventri-cular systolic function by echocardiography: a systematic re-view of 3 methods. Am Heart J 2003;146:388-97.
190. Faber TL, Cooke CD, Folks RD, Vansant JP, Nichols KJ, DePuey EG, Pettigrew RI, Garcia EV. Left ventricular function and per-fusion from gated SPECT perfusion images: an integrated method. J Nucl Med 1999;40:650-9.
191. Nakajima K, Nishimura T. Inter-institution preference-based variability of ejection fraction and volumes using quantitative gated SPECT with 99mTc-tetrofosmin: a multicentre study involving 106 hospitals. Eur J Nucl Med Mol Imaging 2006;33:127-33.
192. Koch JA, Poll LW, Godehardt E, Korbmacher B, Modder U. Right and left ventricular volume measurements in an animal heart model in vitro: first experiences with cardiac MRI at 1.0 T. Eur Radiol 2000;10:455-8.
193. Møgelvang J, Stokholm KH, Saunamaki K, Reimer A, Stub-gaard M, Thomsen C, Fritz-Hansen P, Henriksen O. Assess-ment of left ventricular volumes by magnetic resonance in comparison with radionuclide angiography, contrast angio-graphy and echocardiography. Eur Heart J 1992;13:1677-83.
194. Florentine MS, Grosskreutz CL, Chang W, Hartnett JA, Dunn VD, Ehrhardt JC, Fleagle SR, Collins SM, Marcus ML, Skorton DJ. Measurement of left ventricular mass in vivo using gated nuclear magnetic resonance imaging. J Am Coll Cardiol 1986;8:107-12.
195. Mogelvang J, Lindvig K, Sondergaard L, Saunamaki K, Henrik-sen O. Reproducibility of cardiac volume measurements in-cluding left ventricular mass determined by MRI. Clin Physiol 1993;13:587-97.
196. Semelka RC, Tomei E, Wagner S, Mayo J, Caputo G, O'Sullivan M, Parmley WW, Chatterjee K, Wolfe C, Higgins CB. Interstu-dy reproducibility of dimensional and functional measure-ments between cine magnetic resonance studies in the mor-phologically abnormal left ventricle. Am Heart J 1990;119:1367-73.
197. Schwitter J, Nanz D, Kneifel S, Bertschinger K, Buchi M, Knu-sel PR, Marincek B, Luscher TF, von Schulthess GK. Assess-ment of myocardial perfusion in coronary artery disease by magnetic resonance: a comparison with positron emission tomography and coronary angiography. Circulation 2001;103:2230-5.
198. Ibrahim T, Nekolla SG, Schreiber K, Odaka K, Volz S, Mehilli J, Guthlin M, Delius W, Schwaiger M. Assessment of coronary flow reserve: comparison between contrast-enhanced mag-netic resonance imaging and positron emission tomography. J Am Coll Cardiol 2002;39:864-70.
199. Nagel E, Klein C, Paetsch I, Hettwer S, Schnackenburg B, Wegscheider K, Fleck E. Magnetic resonance perfusion mea-surements for the noninvasive detection of coronary artery disease. Circulation 2003;108:432-7.
200. Sakuma H, Suzawa N, Ichikawa Y, Makino K, Hirano T, Kita-gawa K, Takeda K. Diagnostic accuracy of stress first-pass contrast-enhanced myocardial perfusion MRI compared with stress myocardial perfusion scintigraphy. AJR Am J Roentge-nol 2005;185:95-102.
201. Marckmann P. An epidemic outbreak of nephrogenic system-ic fibrosis in a Danish hospital. Eur J Radiol 2008;66:187-90.
202. Kalka C, Masuda H, Takahashi T, Gordon R, Tepper O, Grave-reaux E, Pieczek A, Iwaguro H, Hayashi SI, Isner JM, Asahara T. Vascular endothelial growth factor (165) gene transfer augments circulating endothelial progenitor cells in human subjects. Circ Res 2000;86:1198-202.
203. Tomita S, Li RK, Weisel RD, Mickle DA, Kim EJ, Sakai T, Jia ZQ. Autologous transplantation of bone marrow cells improves damaged heart function. Circulation 1999;100:II247-II256.
204. Sesti C, Hale SL, Lutzko C, Kloner RA. Granulocyte colony-stimulating factor and stem cell factor improve contractile reserve of the infarcted left ventricle independent of restor-ing muscle mass. J Am Coll Cardiol 2005;46:1662-9.
205. Kalka C, Masuda H, Takahashi T, Kalka-Moll WM, Silver M, Kearney M, Li T, Isner JM, Asahara T. Transplantation of ex vivo expanded endothelial progenitor cells for therapeutic neovascularization. Proc Natl Acad Sci U S A 2000;97:3422-7.
206. Uemura R, Xu M, Ahmad N, Ashraf M. Bone marrow stem cells prevent left ventricular remodeling of ischemic heart through paracrine signaling. Circ Res 2006;98:1414-21.
207. Orlic D, Kajstura J, Chimenti S, Limana F, Jakoniuk I, Quaini F, Nadal-Ginard B, Bodine DM, Leri A, Anversa P. Mobilized bone marrow cells repair the infarcted heart, improving function and survival. Proc Natl Acad Sci U S A 2001;98:10344-9.
208. Wang Y, Tägil K, Ripa RS, Nilsson JC, Carstensen S, Jørgensen E, Søndergaard L, Hesse B, Johnsen HE, Kastrup J. Effect of mobilization of bone marrow stem cells by granulocyte colo-ny stimulating factor on clinical symptoms, left ventricular perfusion and function in patients with severe chronic ischemic heart disease. Int J Cardiol 2005;100:477-83.
209. Seiler C, Pohl T, Wustmann K, Hutter D, Nicolet PA, Windeck-er S, Eberli FR, Meier B. Promotion of collateral growth by granulocyte-macrophage colony-stimulating factor in patients with coronary artery disease: a randomized, double-blind, placebo-controlled study. Circulation 2001;104:2012-7.
210. Tateishi-Yuyama E, Matsubara H, Murohara T, Ikeda U, Shin-tani S, Masaki H, Amano K, Kishimoto Y, Yoshimoto K, Akashi H, Shimada K, Iwasaka T, Imaizumi T. Therapeutic angiogene-sis for patients with limb ischaemia by autologous transplan-tation of bone-marrow cells: a pilot study and a randomised controlled trial. Lancet 2002;360:427-35.
211. Ripa RS, Wang Y, Jørgensen E, Johnsen HE, Grande P, Kastrup J. Safety of bone-marrow stem cell mobilisation induced by granulocyte-colony stimulating factor: Clinical 30 days blinded results from the stem cells in myocardial infarction (STEMMI) trial. Heart Drug 2005;5:177-82.
212. Hill JM, Syed MA, Arai AE, Powell TM, Paul JD, Zalos G, Read EJ, Khuu HM, Leitman SF, Horne M, Csako G, Dunbar CE, Waclawiw MA, Cannon RO, III. Outcomes and risks of granu-locyte colony-stimulating factor in patients with coronary ar-tery disease. J Am Coll Cardiol 2005;46:1643-8.
213. Boyle AJ, Whitbourn R, Schlicht S, Krum H, Kocher A, Nan-durkar H, Bergmann S, Daniell M, O'Day J, Skerrett D, Hay-lock D, Gilbert RE, Itescu S. Intra-coronary high-dose CD34+ stem cells in patients with chronic ischemic heart disease: a 12-month follow-up. Int J Cardiol 2006;109:21-7.
214. Kovacic JC, Macdonald P, Feneley MP, Muller DWM, Freund J, Dodds A, Milliken S, Tao H, Itescu S, Moore J, Ma D, Gra-ham RM. Safety and efficacy of consecutive cycles of granu-locyte-colony stimulating factor, and an intracoronary CD133+ cell infusion in patients with chronic refractory ischemic heart disease: The G-CSF in Angina patients with IHD to stimulate Neovascularization (GAIN I) trial. Am Heart J 2008;156:954-63.
215. Losordo DW, Schatz RA, White CJ, Udelson JE, Veereshwa-rayya V, Durgin M, Poh KK, Weinstein R, Kearney M, Chaud-hry M, Burg A, Eaton L, Heyd L, Thorne T, Shturman L, Hoff-meister P, Story K, Zak V, Dowling D, Traverse JH, Olson RE, Flanagan J, Sodano D, Murayama T, Kawamoto A, Kusano KF, Wollins J, Welt F, Shah P, Soukas P, Asahara T, Henry TD. Intramyocardial transplantation of autologous CD34+ stem cells for intractable angina: a phase I/IIa double-blind, ran-domized controlled trial. Circulation 2007;115:3165-72.
216. Kawamoto A, Murayama T, Kusano K, Ii M, Tkebuchava T, Shintani S, Iwakura A, Johnson I, von Samson P, Hanley A, Gavin M, Curry C, Silver M, Ma H, Kearney M, Losordo DW. Synergistic effect of bone marrow mobilization and vascular endothelial growth factor-2 gene therapy in myocardial ischemia. Circulation 2004;110:1398-405.
217. Shintani S, Kusano K, Ii M, Iwakura A, Heyd L, Curry C, Weck-er A, Gavin M, Ma H, Kearney M, Silver M, Thorne T, Muro-hara T, Losordo DW. Synergistic effect of combined intra-myocardial CD34+ cells and VEGF2 gene therapy after MI. Nat Clin Pract Cardiovasc Med 2006;3 Suppl 1:S123-S128.
218. Baldazzi F, Jørgensen E, Ripa RS, Kastrup J. Release of bio-markers of myocardial damage after direct intramyocardial injection of genes and stem cells via the percutaneous trans-luminal route. Eur Heart J 2008;29:1819-26.
219. Wang Y, Ripa RS, Jørgensen E, Hesse B, Mortensen S, Kastrup J. Mobilization of haematopoietic and non-haematopoietic cells by granulocyte-colony stimulating factor and vascular endothelial growth factor gene therapy in patients with sta-ble severe coronary artery disease. Scand Cardiovasc J 2007;41:397-404.
220. Powell TM, Paul JD, Hill JM, Thompson M, Benjamin M, Rodrigo M, McCoy JP, Read EJ, Khuu HM, Leitman SF, Finkel T, Cannon RO, III. Granulocyte colony-stimulating factor mo-bilizes functional endothelial progenitor cells in patients with coronary artery disease. Arterioscler Thromb Vasc Biol 2005;25:296-301.
221. Takai H, Miyoshi A, Yamazaki M, Adachi K, Katagiri K, Araka-wa H, Katsuyama K, Ito T, Fujii E, Hayashi S, Kato A, Suzuki M. Granulocyte colony-stimulating factor has no adverse effects on atherosclerotic lesions in high cholesterol-fed miniature Swine. J Vet Med Sci 2008;70:943-50.
222. Chih, Sharon S., Macdonald, Peter, McCrohon, Jane A., Ma, David, John, Moore, Law, Matthew, Feneley, Michael P., Herbert, Andrea, Kovacic, Jason C., and Graham, Robert M. Granulocyte-colony stimulating factor in angina patients with ischaemic heart diesase to stimulate neovascularisation (GAIN II trial). J Am Coll Cardiol 2010;55:A126. E1184 [Ab-stract]
223. Meier P, Gloekler S, de Marchi SF, Indermuehle A, Rutz T, Traupe T, Steck H, Vogel R, Seiler C. Myocardial salvage through coronary collateral growth by granulocyte colony-stimulating factor in chronic coronary artery disease: a con-trolled randomized trial. Circulation 2009;120:1355-63.
224. Goetze JP, Yongzhong W, Rehfeld JF, Jørgensen E, Kastrup J. Coronary angiography transiently increases plasma pro-B-type natriuretic peptide. Eur Heart J 2004;25:759-64.
225. Wang Y, Gabrielsen A, Lawler PR, Paulsson-Berne G, Stein-bruchel DA, Hansson GK, Kastrup J. Myocardial gene expres-sion of angiogenic factors in human chronic ischemic myo-cardium: influence of acute ischemia/cardioplegia and reperfusion. Microcirculation 2006;13:187-97.
226. Wynn RF, Hart CA, Corradi-Perini C, O'Neill L, Evans CA, Wraith JE, Fairbairn LJ, Bellantuono I. A small proportion of mesenchymal stem cells strongly expresses functionally ac-tive CXCR4 receptor capable of promoting migration to bone marrow. Blood 2004;104:2643-5.
227. Rentrop KP, Cohen M, Blanke H, Phillips RA. Changes in collateral channel filling immediately after controlled coro-nary artery occlusion by an angioplasty balloon in human subjects. J Am Coll Cardiol 1985;5:587-92.
228. Werner GS, Ferrari M, Heinke S, Kuethe F, Surber R, Richartz BM, Figulla HR. Angiographic assessment of collateral con-nections in comparison with invasively determined collateral function in chronic coronary occlusions. Circulation 2003;107:1972-7.
229. van der MP, De Boer RA, White HL, van der SG, Hall AS, Voors AA, van Veldhuisen DJ. The VEGF +405 CC promoter polymorphism is associated with an impaired prognosis in patients with chronic heart failure: a MERIT-HF substudy. J Card Fail 2005;11:279-84.
230. Ray D, Mishra M, Ralph S, Read I, Davies R, Brenchley P. Association of the VEGF gene with proliferative diabetic reti-nopathy but not proteinuria in diabetes. Diabetes 2004;53:861-4.
231. Doi K, Noiri E, Nakao A, Fujita T, Kobayashi S, Tokunaga K. Functional polymorphisms in the vascular endothelial growth factor gene are associated with development of end-stage renal disease in males. J Am Soc Nephrol 2006;17:823-30.
232. Askari AT, Unzek S, Popovic ZB, Goldman CK, Forudi F, Kie-drowski M, Rovner A, Ellis SG, Thomas JD, DiCorleto PE, To-pol EJ, Penn MS. Effect of stromal-cell-derived factor 1 on stem-cell homing and tissue regeneration in ischaemic cardi-omyopathy. Lancet 2003;362:697-703.
233. Grunewald M, Avraham I, Dor Y, Bachar-Lustig E, Itin A, Jung S, Chimenti S, Landsman L, Abramovitch R, Keshet E. VEGF-induced adult neovascularization: recruitment, retention, and role of accessory cells. Cell 2006;124:175-89.
234. Peled A, Grabovsky V, Habler L, Sandbank J, renzana-Seisdedos F, Petit I, Ben-Hur H, Lapidot T, Alon R. The che-mokine SDF-1 stimulates integrin-mediated arrest of CD34 (+) cells on vascular endothelium under shear flow. J Clin Invest 1999;104:1199-211.
235. De FE, Porcelli D, Torella AR, Straino S, Iachininoto MG, Or-landi A, Truffa S, Biglioli P, Napolitano M, Capogrossi MC, Pesce M. SDF-1 involvement in endothelial phenotype and ischemia-induced recruitment of bone marrow progenitor cells. Blood 2004;104:3472-82.
236. Peled A, Kollet O, Ponomaryov T, Petit I, Franitza S, Gra-bovsky V, Slav MM, Nagler A, Lider O, Alon R, Zipori D, Lapi-dot T. The chemokine SDF-1 activates the integrins LFA-1, VLA-4, and VLA-5 on immature human CD34 (+) cells: role in transendothelial/stromal migration and engraftment of NOD/SCID mice. Blood 2000;95:3289-96.
237. Chavakis E, Aicher A, Heeschen C, Sasaki K, Kaiser R, El MN, Urbich C, Peters T, Scharffetter-Kochanek K, Zeiher AM, Cha-vakis T, Dimmeler S. Role of beta2-integrins for homing and neovascularization capacity of endothelial progenitor cells. J Exp Med 2005;201:63-72.
238. Urbich C, Heeschen C, Aicher A, Sasaki K, Bruhl T, Farhadi MR, Vajkoczy P, Hofmann WK, Peters C, Pennacchio LA, Ab-olmaali ND, Chavakis E, Reinheckel T, Zeiher AM, Dimmeler S. Cathepsin L is required for endothelial progenitor cell-induced neovascularization. Nat Med 2005;11:206-13.
239. van Weel V, Seghers L, de Vries MR, Kuiper EJ, Schlingemann RO, Bajema IM, Lindeman JH, is-van Diemen PM, van H, V, van Bockel JH, Quax PH. Expression of vascular endothelial growth factor, stromal cell-derived factor-1, and CXCR4 in human limb muscle with acute and chronic ischemia. Arteri-oscler Thromb Vasc Biol 2007;27:1426-32.
240. Heeschen C, Lehmann R, Honold J, Assmus B, Aicher A, Wal-ter DH, Martin H, Zeiher AM, Dimmeler S. Profoundly re-duced neovascularization capacity of bone marrow mono-nuclear cells derived from patients with chronic ischemic heart disease. Circulation 2004;109:1615-22.
241. Li TS, Kubo M, Ueda K, Murakami M, Ohshima M, Kobayashi T, Tanaka T, Shirasawa B, Mikamo A, Hamano K. Identifica-tion of risk factors related to poor angiogenic potency of bone marrow cells from different patients. Circulation 2009;120:S255-S261.
242. Friis T, Haack-Sorensen M, Hansen SK, Hansen L, Bindslev L, Kastrup J. Comparison of Mesenchymal Stromal Cells From Young Healthy Donors and Patients With Severe Chronic Co-ronary Artery Disease. Scand J Clin Lab Invest In press 2011.
243. Suuronen EJ, Hazra S, Zhang P, Vincent R, Kumarathasan P, Zhang Y, Price J, Chan V, Sellke FW, Mesana TG, Veinot JP, Ruel M. Impairment of human cell-based vasculogenesis in rats by hypercholesterolemia-induced endothelial dysfunc-tion and rescue with L-arginine supplementation. J Thorac Cardiovasc Surg 2010;139:209-16.
244. Murohara T, Asahara T, Silver M, Bauters C, Masuda H, Kalka C, Kearney M, Chen D, Symes JF, Fishman MC, Huang PL, Isn-er JM. Nitric oxide synthase modulates angiogenesis in re-sponse to tissue ischemia. J Clin Invest 1998;101:2567-78.
245. Matsunaga T, Weihrauch DW, Moniz MC, Tessmer J, Warltier DC, Chilian WM. Angiostatin inhibits coronary angiogenesis during impaired production of nitric oxide. Circulation 2002;105:2185-91.
246. Walter DH, Haendeler J, Reinhold J, Rochwalsky U, Seeger F, Honold J, Hoffmann J, Urbich C, Lehmann R, renzana-Seisdesdos F, Aicher A, Heeschen C, Fichtlscherer S, Zeiher AM, Dimmeler S. Impaired CXCR4 signaling contributes to the reduced neovascularization capacity of endothelial pro-genitor cells from patients with coronary artery disease. Circ Res 2005;97:1142-51.
247. Honold J, Lehmann R, Heeschen C, Walter DH, Assmus B, Sasaki K, Martin H, Haendeler J, Zeiher AM, Dimmeler S. Ef-fects of granulocyte colony stimulating factor on functional activities of endothelial progenitor cells in patients with chronic ischemic heart disease. Arterioscler Thromb Vasc Biol 2006;26:2238-43.
248. Brunner S, Huber BC, Fischer R, Groebner M, Hacker M, David R, Zaruba MM, Vallaster M, Rischpler C, Wilke A, Ger-bitz A, Franz WM. G-CSF treatment after myocardial infarc-tion: impact on bone marrow-derived vs cardiac progenitor cells. Exp Hematol 2008;36:695-702.
249. Stein A, Zohlnhofer D, Pogatsa-Murray G, von WJ, Steppich BA, Schomig A, Kastrati A, Ott I. Expression of CXCR4, VLA-1, LFA-3 and transducer of ERB in G-CSF-mobilised progenitor cells in acute myocardial infarction. Thromb Haemost 2010;103:638-43.
250. Suarez de LJ, Torres A, Herrera I, Pan M, Romero M, Pavlovic D, Segura J, Ojeda S, Sanchez J, Lopez RF, Medina A. [Effects of stem-cell mobilization with recombinant human granulo-cyte colony stimulating factor in patients with percutaneous-ly revascularized acute anterior myocardial infarction]. Rev Esp Cardiol 2005;58:253-61.
251. Kuethe F, Figulla HR, Herzau M, Voth M, Fritzenwanger M, Opfermann T, Pachmann K, Krack A, Sayer HG, Gottschild D, Werner GS. Treatment with granulocyte colony-stimulating factor for mobilization of bone marrow cells in patients with acute myocardial infarction. Am Heart J 2005;150:115.
252. Valgimigli M, Rigolin GM, Cittanti C, Malagutti P, Curello S, Percoco G, Bugli AM, Della PM, Bragotti LZ, Ansani L, Mauro E, Lanfranchi A, Giganti M, Feggi L, Castoldi G, Ferrari R. Use of granulocyte-colony stimulating factor during acute myo-cardial infarction to enhance bone marrow stem cell mobili-zation in humans: clinical and angiographic safety profile. Eur Heart J 2005;26:1838-45.
253. Leone AM, Galiuto L, Garramone B, Rutella S, Giannico MB, Brugaletta S, Perfetti M, Liuzzo G, Porto I, Burzotta F, Niccoli G, Biasucci LM, Leone G, Rebuzzi AG, Crea F. Usefulness of granulocyte colony-stimulating factor in patients with a large anterior wall acute myocardial infarction to prevent left ven-tricular remodeling (the rigenera study). Am J Cardiol 2007;100:397-403.
254. Kang HJ, Kim HS, Koo BK, Kim YJ, Lee D, Sohn DW, Oh BH, Park YB. Intracoronary infusion of the mobilized peripheral blood stem cell by G-CSF is better than mobilization alone by G-CSF for improvement of cardiac function and remodeling: 2-year follow-up results of the Myocardial Regeneration and Angiogenesis in Myocardial Infarction with G-CSF and Intra-Coronary Stem Cell Infusion (MAGIC Cell) 1 trial. Am Heart J 2007;153:237-8.
255. Takano H, Hasegawa H, Kuwabara Y, Nakayama T, Matsuno K, Miyazaki Y, Yamamoto M, Fujimoto Y, Okada H, Okubo S, Fujita M, Shindo S, Kobayashi Y, Komiyama N, Takekoshi N, Imai K, Himi T, Ishibashi I, Komuro I. Feasibility and safety of granulocyte colony-stimulating factor treatment in patients with acute myocardial infarction. Int J Cardiol 2007;122:41-7.
256. Ince H, Petzsch M, Kleine HD, Schmidt H, Rehders T, Korber T, Schumichen C, Freund M, Nienaber CA. Preservation from left ventricular remodeling by front-integrated revasculariza-tion and stem cell liberation in evolving acute myocardial in-farction by use of granulocyte-colony-stimulating factor (FIRSTLINE-AMI). Circulation 2005;112:3097-106.
257. Ellis SG, Penn MS, Bolwell B, Garcia M, Chacko M, Wang T, Brezina KJ, McConnell G, Topol EJ. Granulocyte colony stimu-lating factor in patients with large acute myocardial infarc-tion: results of a pilot dose-escalation randomized trial. Am Heart J 2006;152:1051-14.
258. Zohlnhöfer D, Ott I, Mehilli J, Schomig K, Michalk F, Ibrahim T, Meisetschlager G, von Wedel J, Bollwein H, Seyfarth M, Dirschinger J, Schmitt C, Schwaiger M, Kastrati A, Schomig A. Stem cell mobilization by granulocyte colony-stimulating fac-tor in patients with acute myocardial infarction: a rando-mized controlled trial. JAMA 2006;295:1003-10.
259. Engelmann MG, Theiss HD, Hennig-Theiss C, Huber A, Win-tersperger BJ, Werle-Ruedinger AE, Schoenberg SO, Stein-beck G, Franz WM. Autologous bone marrow stem cell mobi-lization induced by granulocyte colony-stimulating factor after subacute ST-segment elevation myocardial infarction undergoing late revascularization: final results from the G-CSF-STEMI (Granulocyte Colony-Stimulating Factor ST-Segment Elevation Myocardial Infarction) trial. J Am Coll Cardiol 2006;48:1712-21.
260. Baks T, van Geuns RJ, Biagini E, Wielopolski P, Mollet NR, Cademartiri F, van der Giessen WJ, Krestin GP, Serruys PW, Duncker DJ, de Feyter PJ. Effects of primary angioplasty for acute myocardial infarction on early and late infarct size and left ventricular wall characteristics. J Am Coll Cardiol 2006;47:40-4.
261. Zohlnhöfer D, Dibra A, Koppara T, de WA, Ripa RS, Kastrup J, Valgimigli M, Schomig A, Kastrati A. Stem cell mobilization by granulocyte colony-stimulating factor for myocardial recov-ery after acute myocardial infarction: a meta-analysis. J Am Coll Cardiol 2008;51:1429-37.
262. Ripa, R. S., Jørgensen, E., and Kastrup, J. Risk of Adverse Events at 5-years Follow-up after Cell Mobilization with Gra-nulocyte-Colony Stimulating Factor After Acute ST-Elevation Myocardial Infarction. Circulation 2010;122:A15055 [Abstract]
263. Kang HJ, Kim HS, Zhang SY, Park KW, Cho HJ, Koo BK, Kim YJ, Soo LD, Sohn DW, Han KS, Oh BH, Lee MM, Park YB. Effects of intracoronary infusion of peripheral blood stem-cells mo-bilised with granulocyte-colony stimulating factor on left ventricular systolic function and restenosis after coronary stenting in myocardial infarction: the MAGIC cell randomised clinical trial. Lancet 2004;363:751-6.
264. Steinwender C, Hofmann R, Kammler J, Kypta A, Pichler R, Maschek W, Schuster G, Gabriel C, Leisch F. Effects of peri-pheral blood stem cell mobilization with granulocyte-colony stimulating factor and their transcoronary transplantation af-ter primary stent implantation for acute myocardial infarc-tion. Am Heart J 2006;151:1296-13.
265. Jørgensen E, Ripa RS, Helqvist S, Wang Y, Johnsen HE, Grande P, Kastrup J. In-stent neo-intimal hyperplasia after stem cell mobilization by granulocyte-colony stimulating factor Prelim-inary intracoronary ultrasound results from a double-blind randomized placebo-controlled study of patients treated with percutaneous coronary intervention for ST-elevation myocardial infarction (STEMMI Trial). Int J Cardiol 2006;111:174-7.
266. Jørgensen E, Baldazzi F, Ripa RS, Friis T, Wang Y, Helqvist S, Kastrup J. Instent neointimal hyperplasia after percutaneous intervention for ST-elevation myocardial infarction and treatment with granulocyte-colony stimulating factor. Re-sults from the stem cells in myocardial infarction (STEMMI) trial. Int J Cardiol 2010;139:269-75.
267. Ince H, Valgimigli M, Petzsch M, de Lezo JS, Kuethe F, Dun-kelmann S, Biondi-Zoccai G, Nienaber CA. Cardiovascular events and re-stenosis following administration of G-CSF in acute myocardial infarction: systematic review and meta-analysis. Heart 2008;94:610-6.
268. Haghighat A, Weiss D, Whalin MK, Cowan DP, Taylor WR. Granulocyte colony-stimulating factor and granulocyte ma-crophage colony-stimulating factor exacerbate atherosclero-sis in apolipoprotein E-deficient mice. Circulation 2007;115:2049-54.
269. Menasche P, Hagege AA, Vilquin JT, Desnos M, Abergel E, Pouzet B, Bel A, Sarateanu S, Scorsin M, Schwartz K, Bruneval P, Benbunan M, Marolleau JP, Duboc D. Autologous skeletal myoblast transplantation for severe postinfarction left ven-tricular dysfunction. J Am Coll Cardiol 2003;41:1078-83.
270. Menasche P, Alfieri O, Janssens S, McKenna W, Reichens-purner H, Trinquart L, Vilquin JT, Marolleau JP, Seymour B, Larghero J, Lake S, Chatellier G, Solomon S, Desnos M, Ha-gege AA. The Myoblast Autologous Grafting in Ischemic Car-diomyopathy (MAGIC) trial: first randomized placebo-controlled study of myoblast transplantation. Circulation 2008;117:1189-200.
271. Kuhlmann MT, Kirchhof P, Klocke R, Hasib L, Stypmann J, Fabritz L, Stelljes M, Tian W, Zwiener M, Mueller M, Kienast J, Breithardt G, Nikol S. G-CSF/SCF reduces inducible arr-hythmias in the infarcted heart potentially via increased connexin43 expression and arteriogenesis. J Exp Med 2006;203:87-97.
272. Overgaard M, Ripa RS, Wang Y, Jørgensen E, Kastrup J. Tim-ing of granulocyte-colony stimulating factor treatment after acute myocardial infarction and recovery of left ventricular function: Results from the STEMMI trial. Int J Cardiol 2010;140:351-5.
273. Engelmann MG, Theiss HD, Theiss C, Huber A, Wintersperger BJ, Werle-Ruedinger AE, Schoenberg SO, Steinbeck G, Franz WM. G-CSF in patients suffering from late revascularized ST elevation myocardial infarction: analysis on the timing of G-CSF administration. Exp Hematol 2008;36:703-9.
274. Meluzin J, Mayer J, Groch L, Janousek S, Hornacek I, Hlino-maz O, Kala P, Panovsky R, Prasek J, Kaminek M, Stanicek J, Klabusay M, Koristek Z, Navratil M, Dusek L, Vinklarkova J. Autologous transplantation of mononuclear bone marrow cells in patients with acute myocardial infarction: the effect of the dose of transplanted cells on myocardial function. Am Heart J 2006;152:975-15.
275. Iwase T, Nagaya N, Fujii T, Itoh T, Murakami S, Matsumoto T, Kangawa K, Kitamura S. Comparison of angiogenic potency between mesenchymal stem cells and mononuclear cells in a rat model of hindlimb ischemia. Cardiovasc Res 2005;66:543-51.
276. Pitchford SC, Furze RC, Jones CP, Wengner AM, Rankin SM. Differential mobilization of subsets of progenitor cells from the bone marrow. Cell Stem Cell 2009;4:62-72.
277. Brouard N, Driessen R, Short B, Simmons PJ. G-CSF increases mesenchymal precursor cell numbers in the bone marrow via an indirect mechanism involving osteoclast-mediated bone resorption. Stem Cell Res 2010;5:65-75.
278. Kawada H, Fujita J, Kinjo K, Matsuzaki Y, Tsuma M, Miyatake H, Muguruma Y, Tsuboi K, Itabashi Y, Ikeda Y, Ogawa S, Oka-no H, Hotta T, Ando K, Fukuda K. Nonhematopoietic mesen-chymal stem cells can be mobilized and differentiate into cardiomyocytes after myocardial infarction. Blood 2004;104:3581-7.
279. Delgaudine M, Lambermont B, Lancellotti P, Roelants V, Walrand S, Vanoverschelde JL, Pierard L, Gothot A, Beguin Y. Effects of granulocyte-colony-stimulating factor on progeni-tor cell mobilization and heart perfusion and function in normal mice. Cytotherapy 2011;13:237-47.
280. Cesselli D, Beltrami AP, Rigo S, Bergamin N, D'Aurizio F, Verardo R, Piazza S, Klaric E, Fanin R, Toffoletto B, Marzinot-to S, Mariuzzi L, Finato N, Pandolfi M, Leri A, Schneider C, Beltrami CA, Anversa P. Multipotent progenitor cells are present in human peripheral blood. Circ Res 2009;104:1225-34.
281. Tatsumi K, Otani H, Sato D, Enoki C, Iwasaka T, Imamura H, Taniuchi S, Kaneko K, Adachi Y, Ikehara S. Granulocyte-colony stimulating factor increases donor mesenchymal stem cells in bone marrow and their mobilization into peripheral circulation but does not repair dystrophic heart after bone marrow transplantation. Circ J 2008;72:1351-8.
282. Delgaudine M, Gothot A, Beguin Y. Spontaneous and granu-locyte-colony-stimulating factor-enhanced marrow response and progenitor cell mobilization in mice after myocardial in-farction. Cytotherapy 2010;12:909-18.
283. Ince H, Petzsch M, Kleine HD, Eckard H, Rehders T, Burska D, Kische S, Freund M, Nienaber CA. Prevention of left ventricu-lar remodeling with granulocyte colony-stimulating factor af-ter acute myocardial infarction: final 1-year results of the Front-Integrated Revascularization and Stem Cell Liberation in Evolving Acute Myocardial Infarction by Granulocyte Colo-ny-Stimulating Factor (FIRSTLINE-AMI) Trial. Circulation 2005;112:I73-I80.
284. Neumann FJ, Blasini R, Schmitt C, Alt E, Dirschinger J, Gawaz M, Kastrati A, Schomig A. Effect of glycoprotein IIb/IIIa recep-tor blockade on recovery of coronary flow and left ventricular function after the placement of coronary-artery stents in acute myocardial infarction. Circulation 1998;98:2695-701.
285. Ofili EO, Kern MJ, St Vrain JA, Donohue TJ, Bach R, al-Joundi B, Aguirre FV, Castello R, Labovitz AJ. Differential characteri-zation of blood flow, velocity, and vascular resistance be-tween proximal and distal normal epicardial human coronary arteries: analysis by intracoronary Doppler spectral flow ve-locity. Am Heart J 1995;130:37-46.
286. Vulliet PR, Greeley M, Halloran SM, MacDonald KA, Kittleson MD. Intra-coronary arterial injection of mesenchymal strom-al cells and microinfarction in dogs. Lancet 2004;363:783-4.
287. Kang HJ, Lee HY, Na SH, Chang SA, Park KW, Kim HK, Kim SY, Chang HJ, Lee W, Kang WJ, Koo BK, Kim YJ, Lee DS, Sohn DW, Han KS, Oh BH, Park YB, Kim HS. Differential effect of intra-coronary infusion of mobilized peripheral blood stem cells by granulocyte colony-stimulating factor on left ventricular function and remodeling in patients with acute myocardial infarction versus old myocardial infarction: the MAGIC Cell-3-DES randomized, controlled trial. Circulation 2006;114:I145-I151.
288. Lutz M, Rosenberg M, Kiessling F, Eckstein V, Heger T, Krebs J, Ho AD, Katus HA, Frey N. Local injection of stem cell factor (SCF) improves myocardial homing of systemically delivered c-kit + bone marrow-derived stem cells. Cardiovasc Res 2008;77:143-50.
289. Theiss HD, Brenner C, Engelmann MG, Zaruba MM, Huber B, Henschel V, Mansmann U, Wintersperger B, Reiser M, Stein-beck G, Franz WM. Safety and efficacy of SITAgliptin plus GRanulocyte-colony-stimulating factor in patients suffering from Acute Myocardial Infarction (SITAGRAMI-Trial)--rationale, design and first interim analysis. Int J Cardiol 2010;145:282-4.
290. Baks T, van Geuns RJ, Biagini E, Wielopolski P, Mollet NR, Cademartiri F, Boersma E, van der Giessen WJ, Krestin GP, Duncker DJ, Serruys PW, de Feyter PJ. Recovery of left ven-tricular function after primary angioplasty for acute myocar-dial infarction. Eur Heart J 2005;26:1070-7.
291. Brodie BR, Stuckey TD, Kissling G, Hansen CJ, Weintraub RA, Kelly TA. Importance of infarct-related artery patency for re-covery of left ventricular function and late survival after pri-mary angioplasty for acute myocardial infarction. J Am Coll Cardiol 1996;28:319-25.
292. Stone GW, Grines CL, Cox DA, Garcia E, Tcheng JE, Griffin JJ, Guagliumi G, Stuckey T, Turco M, Carroll JD, Rutherford BD, Lansky AJ. Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. N Engl J Med 2002;346:957-66.
293. Jørgensen E, Madsen T, Kastrup J. Comparison of the left ventricular electromechanical map before percutaneous co-ronary stent revascularization and at one-month follow-up in patients with a recent ST elevation infarction. Catheter Car-diovasc Interv 2005;64:153-9.
294. Schroeder AP, Houlind K, Pedersen EM, Nielsen TT, Egeblad H. Serial magnetic resonance imaging of global and regional left ventricular remodeling during 1 year after acute myocar-dial infarction. Cardiology 2001;96:106-14.
295. Petersen SE, Voigtlander T, Kreitner KF, Horstick G, Ziegler S, Wittlinger T, Abegunewardene N, Schmitt M, Schreiber WG, Kalden P, Mohrs OK, Lippold R, Thelen M, Meyer J. Late im-provement of regional wall motion after the subacute phase of myocardial infarction treated by acute PTCA in a 6-month follow-up. J Cardiovasc Magn Reson 2003;5:487-95.
296. Nijveldt R, Beek AM, Hirsch A, Stoel MG, Hofman MB, Umans VA, Algra PR, Twisk JW, van Rossum AC. Functional recovery after acute myocardial infarction: comparison between angi-ography, electrocardiography, and cardiovascular magnetic resonance measures of microvascular injury. J Am Coll Car-diol 2008;52:181-9.
297. Dill T, Schachinger V, Rolf A, Mollmann S, Thiele H, Tillmanns H, Assmus B, Dimmeler S, Zeiher AM, Hamm C. Intracoronary administration of bone marrow-derived progenitor cells im-proves left ventricular function in patients at risk for adverse remodeling after acute ST-segment elevation myocardial in-farction: results of the Reinfusion of Enriched Progenitor cells And Infarct Remodeling in Acute Myocardial Infarction study (REPAIR-AMI) cardiac magnetic resonance imaging substudy. Am Heart J 2009;157:541-7.
298. Gerber BL, Wijns W, Vanoverschelde JL, Heyndrickx GR, De BB, Bartunek J, Melin JA. Myocardial perfusion and oxygen consumption in reperfused noninfarcted dysfunctional myo-cardium after unstable angina: direct evidence for myocardi-al stunning in humans. J Am Coll Cardiol 1999;34:1939-46.
299. Hombach V, Grebe O, Merkle N, Waldenmaier S, Hoher M, Kochs M, Wohrle J, Kestler HA. Sequelae of acute myocardial infarction regarding cardiac structure and function and their prognostic significance as assessed by magnetic resonance imaging. Eur Heart J 2005;26:549-57.
300. Fieno DS, Hillenbrand HB, Rehwald WG, Harris KR, Decker RS, Parker MA, Klocke FJ, Kim RJ, Judd RM. Infarct resorption, compensatory hypertrophy, and differing patterns of ventri-cular remodeling following myocardial infarctions of varying size. J Am Coll Cardiol 2004;43:2124-31.
301. Richard V, Murry CE, Reimer KA. Healing of myocardial in-farcts in dogs. Effects of late reperfusion. Circulation 1995;92:1891-901.
302. Rogers WJ, Jr., Kramer CM, Geskin G, Hu YL, Theobald TM, Vido DA, Petruolo S, Reichek N. Early contrast-enhanced MRI predicts late functional recovery after reperfused myocardial infarction. Circulation 1999;99:744-50.
303. Saeed M, Lund G, Wendland MF, Bremerich J, Weinmann H, Higgins CB. Magnetic resonance characterization of the peri-infarction zone of reperfused myocardial infarction with ne-crosis-specific and extracellular nonspecific contrast media. Circulation 2001;103:871-6.
304. Oshinski JN, Yang Z, Jones JR, Mata JF, French BA. Imaging time after Gd-DTPA injection is critical in using delayed en-hancement to determine infarct size accurately with magnet-ic resonance imaging. Circulation 2001;104:2838-42.
305. Kim RJ, Fieno DS, Parrish TB, Harris K, Chen EL, Simonetti O, Bundy J, Finn JP, Klocke FJ, Judd RM. Relationship of MRI de-layed contrast enhancement to irreversible injury, infarct age, and contractile function. Circulation 1999;100:1992-2002.
306. Fieno DS, Kim RJ, Chen EL, Lomasney JW, Klocke FJ, Judd RM. Contrast-enhanced magnetic resonance imaging of myocar-dium at risk: distinction between reversible and irreversible injury throughout infarct healing. J Am Coll Cardiol 2000;36:1985-91.
307. Lipinski MJ, Biondi-Zoccai GG, Abbate A, Khianey R, Sheiban I, Bartunek J, Vanderheyden M, Kim HS, Kang HJ, Strauer BE, Vetrovec GW. Impact of intracoronary cell therapy on left ventricular function in the setting of acute myocardial infarc-tion: a collaborative systematic review and meta-analysis of controlled clinical trials. J Am Coll Cardiol 2007;50:1761-7.
308. Kawamoto A, Iwasaki H, Kusano K, Murayama T, Oyamada A, Silver M, Hulbert C, Gavin M, Hanley A, Ma H, Kearney M, Zak V, Asahara T, Losordo DW. CD34-positive cells exhibit in-creased potency and safety for therapeutic neovasculariza-tion after myocardial infarction compared with total mono-nuclear cells. Circulation 2006;114:2163-9.
309. Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, Moorman MA, Simonetti DW, Craig S, Marshak DR. Multilineage potential of adult human mesenchymal stem cells. Science 1999;284:143-7.
310. Haack-Sørensen M, Friis T, Bindslev L, Mortensen S, Johnsen HE, Kastrup J. Comparison of different culture conditions for human mesenchymal stromal cells for clinical stem cell ther-apy. Scand J Clin Lab Invest 2008;68:192-203.
311. Haack-Sørensen M, Friis T, Kastrup J. Mesenchymal stromal cell and mononuclear cell therapy in heart disease. Future Cardiology 2008;4:481-94.
312. Hare JM, Traverse JH, Henry TD, Dib N, Strumpf RK, Schul-man SP, Gerstenblith G, DeMaria AN, Denktas AE, Gammon RS, Hermiller JB, Jr., Reisman MA, Schaer GL, Sherman W. A randomized, double-blind, placebo-controlled, dose-escalation study of intravenous adult human mesenchymal stem cells (prochymal) after acute myocardial infarction. J Am Coll Cardiol 2009;54:2277-86.
313. Hofmann M, Wollert KC, Meyer GP, Menke A, Arseniev L, Hertenstein B, Ganser A, Knapp WH, Drexler H. Monitoring of bone marrow cell homing into the infarcted human myo-cardium. Circulation 2005;111:2198-202.
314. He G, Zhang H, Wei H, Wang Y, Zhang X, Tang Y, Wei Y, Hu S. In vivo imaging of bone marrow mesenchymal stem cells transplanted into myocardium using magnetic resonance im-aging: a novel method to trace the transplanted cells. Int J Cardiol 2007;114:4-10.
315. Kjær A, Lebech AM. [Leukocyte scintigraphy: indications and diagnostic value]. Ugeskr Laeger 2001;163:4380-4.
316. Jin Y, Kong H, Stodilka RZ, Wells RG, Zabel P, Merrifield PA, Sykes J, Prato FS. Determining the minimum number of de-tectable cardiac-transplanted 111In-tropolone-labelled bone-marrow-derived mesenchymal stem cells by SPECT. Phys Med Biol 2005;50:4445-55.
317. Gholamrezanezhad A, Mirpour S, Ardekani JM, Bagheri M, Alimoghadam K, Yarmand S, Malekzadeh R. Cytotoxicity of 111In-oxine on mesenchymal stem cells: a time-dependent adverse effect. Nucl Med Commun 2009;30:210-6.
318. Bindslev L, Haack-Sørensen M, Bisgaard K, Kragh L, Morten-sen S, Hesse B, Kjaer A, Kastrup J. Labelling of human mesen-chymal stem cells with indium-111 for SPECT imaging: effect on cell proliferation and differentiation. Eur J Nucl Med Mol Imaging 2006;33:1171-7.
319. Schächinger V, Aicher A, Dobert N, Rover R, Diener J, Fichtl-scherer S, Assmus B, Seeger FH, Menzel C, Brenner W, Dim-meler S, Zeiher AM. Pilot trial on determinants of progenitor cell recruitment to the infarcted human myocardium. Circu-lation 2008;118:1425-32.
320. Goussetis E, Manginas A, Koutelou M, Peristeri I, Theodosaki M, Kollaros N, Leontiadis E, Theodorakos A, Paterakis G, Ka-ratasakis G, Cokkinos DV, Graphakos S. Intracoronary infu-sion of CD133+ and CD133-CD34+ selected autologous bone marrow progenitor cells in patients with chronic ischemic cardiomyopathy: cell isolation, adherence to the infarcted area, and body distribution. Stem Cells 2006;24:2279-83.
321. Caveliers V, De KG, Everaert H, Van R, I, Van CG, Verheye S, Roland J, Schoors D, Franken PR, Schots R. In vivo visualiza-tion of 111In labeled CD133+ peripheral blood stem cells af-ter intracoronary administration in patients with chronic ischemic heart disease. Q J Nucl Med Mol Imaging 2007;51:61-6.
322. Kurpisz M, Czepczynski R, Grygielska B, Majewski M, Fiszer D, Jerzykowska O, Sowinski J, Siminiak T. Bone marrow stem cell imaging after intracoronary administration. Int J Cardiol 2007;121:194-5.
323. Zhou R, Thomas DH, Qiao H, Bal HS, Choi SR, Alavi A, Ferrari VA, Kung HF, Acton PD. In vivo detection of stem cells grafted in infarcted rat myocardium. J Nucl Med 2005;46:816-22.
324. Tossios P, Krausgrill B, Schmidt M, Fischer T, Halbach M, Fries JW, Fahnenstich S, Frommolt P, Heppelmann I, Schmidt A, Schomacker K, Fischer JH, Bloch W, Mehlhorn U, Schwinger RH, Muller-Ehmsen J. Role of balloon occlusion for mononuc-lear bone marrow cell deposition after intracoronary injec-tion in pigs with reperfused myocardial infarction. Eur Heart J 2008;29:1911-21.
325. Aicher A, Brenner W, Zuhayra M, Badorff C, Massoudi S, Assmus B, Eckey T, Henze E, Zeiher AM, Dimmeler S. Assess-ment of the tissue distribution of transplanted human endo-thelial progenitor cells by radioactive labeling. Circulation 2003;107:2134-9.
326. Brenner W, Aicher A, Eckey T, Massoudi S, Zuhayra M, Koehl U, Heeschen C, Kampen WU, Zeiher AM, Dimmeler S, Henze E. 111In-labeled CD34+ hematopoietic progenitor cells in a rat myocardial infarction model. J Nucl Med 2004;45:512-8.
327. Hou D, Youssef EA, Brinton TJ, Zhang P, Rogers P, Price ET, Yeung AC, Johnstone BH, Yock PG, March KL. Radiolabeled cell distribution after intramyocardial, intracoronary, and in-terstitial retrograde coronary venous delivery: implications for current clinical trials. Circulation 2005;112:I150-I156.
328. Amsalem Y, Mardor Y, Feinberg MS, Landa N, Miller L, Da-niels D, Ocherashvilli A, Holbova R, Yosef O, Barbash IM, Leor J. Iron-oxide labeling and outcome of transplanted mesen-chymal stem cells in the infarcted myocardium. Circulation 2007;116:I38-I45.
329. Terrovitis J, Stuber M, Youssef A, Preece S, Leppo M, Kizana E, Schar M, Gerstenblith G, Weiss RG, Marban E, Abraham MR. Magnetic resonance imaging overestimates ferumoxide-labeled stem cell survival after transplantation in the heart. Circulation 2008;117:1555-62.
330. Gyongyosi M, Blanco J, Marian T, Tron L, Petnehazy O, Petra-si Z, Hemetsberger R, Rodriguez J, Font G, Pavo IJ, Kertesz I, Balkay L, Pavo N, Posa A, Emri M, Galuska L, Kraitchman DL, Wojta J, Huber K, Glogar D. Serial Noninvasive In Vivo Posi-tron Emission Tomographic Tracking of Percutaneously Intramyocardially Injected Autologous Porcine Mesenchymal Stem Cells Modified for Transgene Reporter Gene Expres-sion. Circ Cardiovasc Imaging 2008;1:94-103.
331. Zimmermann WH, Melnychenko I, Wasmeier G, Didie M, Naito H, Nixdorff U, Hess A, Budinsky L, Brune K, Michaelis B, Dhein S, Schwoerer A, Ehmke H, Eschenhagen T. Engineered heart tissue grafts improve systolic and diastolic function in infarcted rat hearts. Nat Med 2006;12:452-8.
332. Feinberg AW, Feigel A, Shevkoplyas SS, Sheehy S, Whitesides GM, Parker KK. Muscular thin films for building actuators and powering devices. Science 2007;317:1366-70.